I. INTRODUCTION
The heart functions as a mechanical pump ensuring a continuous systemic and pulmonary blood supply. The circulation provides the essential transport of nutrients, antibodies, hormones, and other chemical mediators, as well as the exchange of gases and removal of waste products. Under normal physiological, i.e., nondiseased conditions, the heart works steadily and uninterruptedly, only changing rate according to changes in systemic needs. A human heart thus performs ϳ100,000 successful and coordinated contractions every day. These contractions are controlled by electrical signals, known as action potentials, which trigger an intracellular signaling pathway referred to as the excitation-contraction coupling leading to the muscle contraction (41). The tight electrical control of cardiac contractions also means that imbalances can lead to disturbances in the heart rhythm. In fact, under certain conditions, a single inappropriate electrical signal can obliterate proper cardiac function and ultimately develop into sudden cardiac arrest. Any deviation from the normal stable heart rhythm is categorized as an arrhythmia (from Greek a ϩ rhythmos ϭ loss of rhythm). Arrhythmias are often diagnosed based on irregularities of the surface electrocardiogram (ECG), which macroscopically depicts the electrical activity of the heart. The ECG is divided into different phases (FIGURE 1) that reflect the depolarization and repolarization of atria and ventricles.
Arrhythmias span the entire spectrum from the simplest isolated event of a diminutive palpitation to uncoordinated chaotic signaling recognized as fibrillations. The latter is especially dangerous in a context where fibrillation propagates in the ventricles. Unless quickly terminated, ventricular fibrillation can result in sudden cardiac death, as it invalidates coordinated pumping activity. Arrhythmias are, however, unusual events in young and middle-aged people, which is comforting and also indicates the presence of a broad safety margin and tight control of the complicated and multifaceted processes of electrical signaling and excitation-contraction coupling. In combination with partly overlapping functions for a number of the proteins involved in these mechanisms, this ensures a high level of fidelity and stability in the cardiac system.
The high lipophilicity of cell membranes, including those of cardiac myocytes, provides an effective separation barrier between the cell interior and the extracellular surroundings. The cell membrane is impermeable to the hydrophilic ions, but special transmembrane proteins such as ion channels and transporters enable the different ion species to permeate selectively, and they form the basis for a controlled electrical communication across the cell membrane as the ions carry electrical charges. Fast transient changes in ion permeability generate action potentials and thereby excitability. This is primarily achieved by delicate control of the opening and closing of a number of different ion channels in various parts of the heart. Cardiac action potentials are different from their neuronal counterparts by having an extended plateau phase that will last for several hundred milliseconds in humans and thereby secure the necessary Ca 2ϩ dynamic for appropriate contractions and time for the heart chambers to empty their blood volume. The morphology of the cardiac action potential varies in shape and duration according to the location in the heart (reviewed in Ref. 305 ).
Ventricular action potentials have a relative stable plateau phase and what is recognized as a domelike shape. The exact action potential shape varies to a minor but significant degree in different parts of the ventricle and throughout the ventricular wall. Furthermore, the shape varies over time depending on heart rate, as a fast heart rate speeds up repolarization. Atrial action potentials appear more triangulated in shape, with a less pronounced plateau phase and a more sliding repolarization phase. Action potentials recorded from sinoatrial and atrioventricular nodes exhibit a third kind of shape with a slow onset enabling pacemaker activity. This is accomplished by a sliding resting membrane potential that will elicit spontaneous activity when depolarization is sufficient to reach the threshold for initiation of action potentials. Keeping in mind that ion channels confer the unique signature of action potentials, it follows that a thorough understanding of the regulation and interaction between these channels is a prerequisite for the perception of cardiac function in both a physiological and a pathophysiological context. Representative examples of action potentials obtained from human atria and ventricles are shown in FIGURE 2.
The stability of cardiac electrical signaling is secured by some degree of redundancy in combination with the tight regulation of ion channels as stated above. The various K ϩ channels involved in repolarization of the action potential represent a good example of such partial redundancy. The most thoroughly investigated example is from the ventricles, where three different K ϩ currents participate in the same phase of repolarization. These currents are called I Kr , I Ks , and I K1 , and albeit different in nature, due to different biophysical properties these currents all have a profound and overlapping impact on repolarization of the action potential. This phenomenon has been described as the "repolarization reserve" (364) to emphasize the partly overlapping function and, in this context, the redundancy of the system (FIGURE 2). Various K ϩ channels also participate in the repolarization of atrial action potentials, so there is an equivalent atrial repolarization reserve, including a number of additional K ϩ channel subtypes (FIGURE 2). Some K ϩ channels are believed to be exclusively present in the atria and therefore play important roles for the triangulated shape of atrial action potentials compared with their more domelike ventricular counterparts. Examples of K ϩ channels selectively expressed in the atria encompass K ir 3.1/ K ir 3.4 as responsible for I KACh , K V 1.5 as responsible for I Kur , and, more recently, Ca 2ϩ -activated K ϩ channels accountable for I KCa and two-pore domain K ϩ channels K 2P underlying I leak (51, 102, 122, 132, 166, 250, 302, 471) . Due to their limited distribution, these channels have gained significant interest for many years in the continuing effort to find a treatment for atrial fibrillation without concomitant ventricular adverse effects.
Ion channels are, as stated, of paramount significance for electrical signaling in excitable cells. A thorough insight into the function and regulation of cardiac ion channels is therefore important for the understanding of cardiac physiology and pathophysiology. This review has consequently been devoted to giving a detailed description of cardiac ion channel function and regulation with special emphasis on repolarizing K ϩ channels and their role in arrhythmia. To obtain better perspectives on the nature of arrhythmias and the role of ion channels in this context, we include an introduction to the mechanisms and etiology of arrhythmias. Finally, we cover pharmacological treatments of arrhythmias and the general application of pharmacological tools to obtain better physiological understanding of the heart.
II. ION CHANNELS IN ATRIAL AND VENTRICULAR CARDIOMYOCYTES
The different cardiac ion channels play well-defined roles in shaping the action potential. Although the overall principle is the same in all mammalian cells, the role of repolarizing currents differs significantly. In the heart, it is widely dictated by the great differences in heart rate among species. Humans have a resting heart rate of ϳ60 beats/min (bpm), whereas mice have a heart rate of ϳ600 bpm, which requires repolarizing K ϩ channels with different kinetics. Within the same species, the ion channel expression and thereby the shape and length of the action potential also varies significantly in subregions of the heart, as shown in FIGURE 2. These local differences, especially between atria and ventricles, but also in sinoatrial (SA) and atrioventricular (AV) node, the conduction system and across the ventricular wall, are crucial for the function of these subregions and for the stability of the heart rhythm.
The following section gives a short account of the ion channels responsible for shaping action potential in atria and ventricle with focus on potassium channels. A more detailed description is included for two subtypes of K ϩ channels that traditionally have received relatively little attention. These are the Ca 2ϩ -activated K ϩ channels and two-pore domain K ϩ channels. We further elaborate on the role of accessory subunits, posttranslational modifications, and epigenetic regulation for the major repolarizing potassium currents.
A. Cardiac Action Potential: The Classic Orchestra
The cardiac action potential is divided into five distinct phases (phase 0 -4, as indicated below the action potentials in FIGURE 2). The underlying endogenous currents and their molecular correlates are described below. TABLE 1 gives an overview of potassium currents, their pore-forming ion channel subunits, the principle channel topology, and the genes encoding the channels. For stringency, we follow the nomenclature recommendations of the International Union of Basic and Clinical Pharmacology (IUPHAR) (145, 450, 483) , although trivial channel names, included in TABLE 1 , are widely used in the field.
Phase 0
The abrupt shift in membrane potential in a positive direction (depolarization) that initiates the systolic period is called phase 0 and is driven by influx of Na ϩ , I Na , through the Na V 1.5 channel encoded by the gene SCN5A. The channels are rather insensitive to tetrodotoxin (TTX), which blocks many neuronal Na V channels (126, 482) . The Na V 1.5 current is by far the dominating Na ϩ current in the human heart, but TTX-sensitive currents have been reported (99, 365, 393, 502) . Discrete expression patterns have been shown by immunohistochemistry for Na V 1.1, Na V 1.2, Na V 1.3, Na V 1.4, and Na V 1.6 (encoded by the genes SCN1A, SCN2A, SCN3A, SCN4A, and SCN6A, respectively) (210, 452) . Furthermore, the Na V 1.8 channel protein encoded by SCN10A was reported to be expressed in working myocardium and the cardiac conduction system (475) . Others, however, have found its expression restricted to intracardiac neurons (436) , and the impact of Na V 1.8 on the cardiac sodium current is debated (256) . Whereas Na V 1.5 is the main depolarizing current in atria, conduction system, and ventricle, it is absent in the core of the nodes where Ca V currents are suggested to serve this function, albeit with slower kinetics (271, 305, 323) . Na V 1.5 channels open at potentials positive to Ϫ55 mV, show a steep voltage dependency, and activate very quickly (126) . In addition to the fast peak current, Na V 1.5 channels also conduct a persistent current due to slow or incomplete inactivation at intermediate potentials (23) . Although this persistent or window current only makes up 0.1-1% of the total current (441) , it can significantly impact the action potential morphology and arrhythmogenesis (37, 451).
The Na V 1.5 channels are encoded by the same gene throughout the heart, but functional differences exist between atria and ventricle. The voltage for half-inactivation of Na V 1.5 channels is more negative in atria compared with ventricles in canine and guinea pig (59, 243) , and the resting membrane potentials differ between the two regions, which impacts Na ϩ channel availability and conduction velocity.
Phase 1
The initial depolarization is followed by a transient repolarization termed phase 1, which is most prominent in atria and the ventricular epicardium. This early repolarization is caused by inactivation of Na V 1.5 channels in combination with activation of transient voltage-gated K ϩ currents (I to ) that can further be divided into I to,fast and I to,slow (470) . Both are activated at potentials above Ϫ30 mV and show inactivation. The differences in the two I to components exhibit in their kinetics of inactivation and recovery from inactivation (I to,fast : inactivation ϭ recovery ϭ 20 -100 ms; I to,slow : inactivation ϭ hundreds of ms, recovery ϭ seconds) (311, 335) . The pore-forming subunit of I to,fast is K V 4.2 and K V 4.3 channels, encoded by the genes KCND2 and KCND3, respectively. Additionally, the accessory subunits KChIP2 and DPP6 are necessary to recapitulate native I to,fast (165). In large mammals, I to,fast is primarily formed by K V 4.3 ϩ KChIP2, and the latter shows a stronger epicardial than endocardial expression, causing the I to gradient across the ventricular wall (367, 399) . The K ϩ channel constituting I to,slow is K V 1.4 (KCNA4) (311) . Functionally, the fast repolarization in phase 1 contributes to increasing the driving gradient for Ca 2ϩ into the cardiac myocytes.
Selectively in atria, an additional ultra-rapid current called I Kur contributes to early repolarization. I Kur is conducted by K V 1.5 potassium channels, and silencing K V 1.5 in human atrial myocytes by antisense oligonucleotides causes a major reduction of the I Kur current (122, 359, 397) . Due to its slow and partial inactivation, I Kur plays a role during all phases 1-3, being partly responsible for the triangular action potential shape.
Phase 2
The long-lasting depolarized plateau in phase 2 of the cardiac action potential is a prerequisite for excitation-contraction coupling and is caused by a balance between outward K ϩ currents and inward currents through voltagegated Ca 2ϩ channels. The latter are located in the t tubules, and the Ca 2ϩ influx through these channels activates ryanodine receptors located just below in the sarcoplasmic reticulum. The ensuing Ca 2ϩ -dependent Ca 2ϩ release from intracellular stores triggers muscle contraction (41). There are two types of Ca V channels displaying different expression patterns: the Ca V 1.2 (L-type, gene CACNA1C) ubiquitously expressed in the heart, and the Ca V 3 (T-type) suggested to contribute to the pacemaker function in the nodes (30, 309, 323, 398, 496) . Ca V 3 exists in three isoforms: Ca V 3.1, 3.2, and 3.3. Ca V 3 channels activate at potentials positive to Ϫ50 mV and inactivate quickly, whereas Ca V 1.2 channels require potentials positive to Ϫ30 mV and inactivate slowly, making them the key driver of phase 2 (30, 339). Phase 2 is terminated by a voltage-and Ca 2ϩ /calmodulin-dependent slow inactivation of Ca V 1.2 combined with the simultaneous activation of K ϩ channels (40, 97).
To a lesser extent, the Ca 2ϩ influx in the early part of phase 2 is also transported by the electrogenic Na ϩ /Ca 2ϩ exchanger encoded by the SLC8A1 gene. The stoichiometry of this cotransporter is 3 Na ϩ for 1 Ca 2ϩ , which results in a net movement of a positive charge with a reversal potential around Ϫ30 mV causing influx of Ca 2ϩ and extrusion of Na ϩ during phase 2 in normal hearts (20, 41, 273).
Phase 3
Phase 3 represents the repolarization from plateau phase to resting membrane potential. The repolarization is caused by the balance between inactivating Ca 2ϩ current and rising K ϩ channels tilting quickly towards the latter. In humans and other large mammals, three different potassium currents called I Kr , I Ks , and I K1 are mainly responsible for repolarization. They have diverse but partly overlapping functions, and to stress the latter they have often been called the "repolarization reserve" (FIGURE 2) (364) .
I Kr is conducted by the channel protein K V 11.1, also known as ERG1 or just hERG for the human variant. The K V 11.1 channel is the gene product of KCNH2, and it exists in several splice variants called K V 11.1a, K V 11.1b, and K V 11.1-uso (233) . Functional I Kr is likely to consist of a mixture of both K V 11.1a and K V 11.1b (232, 255) . The presence of accessory ␤-subunits might further be necessary to recapitulate native I Kr , and two of these called KCNE1 and KCNE2 have been described to interact with K V 11.1 (2, 280) . The proposed interaction with KCNE1 has been substantiated by immunoprecipitations from horse heart, indicating a direct interaction (124) , whereas the interaction with KCNE2 remains controversial (116).
I Ks is conducted by the pore forming ␣-subunit K V 7.1 (KCNQ1) in a complex with the ␤-subunit KCNE1 (also known as mink or IsK) (29, 266, 376) . K V 7.1 channels can potentially interact with all ␤-subunits in the KCNE family (KCNE1-5) (279) , since although at different levels, all five subunits are expressed in the heart and modulate the function of K V 7.1 in vitro.
I K1 is conducted via K ir 2.x proteins. This channel family consists of four members K ir 2.1 (IRK1/KCNJ2), K ir 2.2 (IRK2/KCNJ12), K ir 2.3 (IRK3/KCNJ4), and K ir 2.4 (IRK4/ KCNJ14) (47, 53, 226, 413, 421) . Intriguingly, the partly overlapping function of these three currents driving phase 3 repolarization occurs on the basis of very different gating properties. The voltage-gated current I Kr is characterized by a relatively fast activation upon depolarization, but as the inactivation is another 10-fold faster, it renders the channel virtually nonconductive during phases 0 -2 of the action potential (346) . The opposite is true in phase 3, where the initial repolarization will release I Kr from inactivation and reopen the channel. The subsequent deactivation or closure of the channel is a slow process allowing I Kr to conduct current during both phase 3 and the early part of the diastolic phase 4 of the action potential. Although I Ks is also voltage-gated, it displays very different biophysical properties. I Ks opens at potentials positive to Ϫ20 mV and activates slowly. Both the slow activa-tion kinetics and the right-shifted activation curve are largely caused by the presence of the KCNE1 ␤-subunit. Importantly and in contrast to I Kr , I Ks barely inactivates (195, 403) . These properties enable I Ks to build up slowly during phase 2 and to become one of the key K ϩ conductances in phase 3. The third current, I K1 , is not endowed with an inherent voltage sensor in the protein (175) . However, K ir 2.x channels are indirectly voltage sensitive, as the outflow of K ϩ through the channel is accompanied by Mg 2ϩ and polyamines such as spermine that will block the channel deep in the pore (120, 164, 258, 432) . The more positive the membrane potential becomes, the stronger the inhibition and K ir 2.x channels do not conduct K ϩ at potentials more positive than Ϫ20 mV, i.e., in phases 0 -2. When phase 3 repolarization has reached a value of approximately Ϫ40 mV, the K ir 2.x channels will be released from the Mg 2ϩ /spermine inhibition, and I K1 will contribute particularly to repolarization in the late part of phase 3 (258) . I K1 stays open during diastole and is important for setting the resting membrane potential. This is emphasized by the fact that ventricles with high I K1 expression have a resting membrane potential of approximately Ϫ80 mV, while the maximum diastolic potential in nodes lacking I K1 is about Ϫ50 mV (380) . The relative conductances of the three repolarizing currents I Kr , I Ks , and I K1 during the atrial and ventricular action potential and their partly overlapping functions are illustrated in FIGURE 2.
In addition to the "repolarization reserve currents" I Kr , I Ks , and I K1 , other potassium currents can have a significant impact on repolarization of cardiac action potentials. Especially important for the atria are I Kur (see phase 1) and I KACh . I KACh is generally believed to be atria specific, and endogenous I KAch channels are composed of K ir 3.1/K ir 3.4 (or GIRK1/GIRK4) proteins encoded by KCNJ3 and KCNJ5 genes. I KAch is directly activated by interaction with the ␤␥ part of G i proteins connected to muscarinic receptors (178) . Release of acetylcholine following vagal stimulation leads to activation of the cardiac muscarinic receptors. K ir 3.1/ K ir 3.4 channels play an important role in the sinoatrial node, where an increased K ϩ conductance will give rise to a slower depolarization of the pacemaker potential and a reduction of the heart rate (281, 358) . Furthermore, K ir 3.1/K ir 3.4 channels are important for atrial repolarization. Activation of the channels causes a shortening of the atrial action potential. The channel is also activated by adenosine and seems via this mechanism to be able to also repolarize both atrial (445) and ventricular cardiomyocytes (246) .
Finally, I KATP should be mentioned as a potentially important cardiac repolarizing current. The channel is composed of the pore-forming ␣-subunit K ir 6.2 (KCNJ11) in association with the ␤-subunit SUR2A (ABCC9) (59a, 124a) . The channel is abundant throughout the heart, but generally closed due to ATP inhibition at the intracellular surface. Under normal physiological conditions, the intracellular ATP level is sufficiently high to inhibit the channels, but during hypoxia and ischemia, the intracellular ATP level drops and may result in an activation of K ir 6.2 channels (189a). K ir 6.2 channels have a membrane topology similar to K ir 2.x channels conducting I K1 , albeit with less rectification, so they can conduct current throughout phases 0 -3 resulting in triangulation of the action potential.
Phase 4
Phase 4 describes the interval between full repolarization and the initiation of the next action potential. In this diastolic interval, the cardiac myocytes are at resting membrane potential, and the charge movements are primarily conducted via various K ϩ channels, including K ir 2.x and two-pore motif leak channels. Additional K ϩ channels with slow deactivation kinetics, including K V 11.1 and K V 7.1, also remain open in the initial part of phase 4. These K ϩ currents will counteract possible depolarizing events from delayed afterdepolarizations. However, the inhibitory force of the K ϩ conductances is not enough to withstand massive depolarizing stimuli arising from a new wave of action potentials. Prolongation of the effective refractory period through K ϩ channel inhibition and Na ϩ channel inactivation remains the more efficient mechanism.
It is worth mentioning that the duration and degree of hyperpolarization in phase 4 will impact the morphology of the subsequent action potential. The reason is that both Ca 2ϩ and Na ϩ channels undergo voltage-and time-dependent release from inactivation. The number of Na ϩ and Ca 2ϩ channels that can be engaged in a subsequent action potential will therefore increase with duration and extent of hyperpolarization in phase 4.
B. Cardiac Action Potential: New Players
In addition to the well-described currents, in recent years Ca 2ϩ -activated small conductance K ϩ channels (K Ca 2.x) and various two-pore domain channels (K 2P ) have proven to be important cardiac K ϩ channels contributing in particular to atrial repolarization.
Ca 2ϩ -activated K ϩ channels
For many years, Ca 2ϩ -activated K ϩ channels were regarded as absent from cardiac tissue or at least not present in cardiomyocytes. There is increasing evidence of an important functional role for some subtypes of Ca 2ϩ -activated K ϩ channels in the heart. After a brief introduction to the family of Ca 2ϩ -activated K ϩ channels and the pharmacological tools applied to reveal their function, we will provide an overview of the literature evidence for the significance of these channels in cardiac tissue. , Na ϩ , and Cl Ϫ channels. Therefore, apamin has been considered a fingerprint or state-of-the-art inhibitor of K Ca 2.x channels. Whereas in noncardiac tissue such as neurons, skeletal muscle, hepatocytes, and T lymphocytes, apamin is used broadly as a tool to address the physiological roles of K Ca 2.x channels, the experiences from using the large apamin molecule as a tool compound on cardiac tissue are less convincing (28, 46, 101, 191, 354, 396) . A number of alternatives to apamin exist, including peptide toxins such as scorpion toxins scyllatoxin and tamapin (406, 465) , and small organic molecules such as tubocurarine, UCL1684, or N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (138, 248, 366, 465) . A completely different class of selective K Ca 2.x channel inhibitors was introduced by the small organic compound NS8593, which has a different binding site than apamin (194, 400, 408) (FIGURE 3D ). NS8593 acts as a negative gating modifier that decreases the Ca 2ϩ sensitivity by rightward shifting the Ca 2ϩ -activation curve (408) .
The first indirect evidence for the presence of cardiac K Ca 2.x channels appeared more than 40 years ago. In a technical report from Edgewood Arsenal, Maryland, apamin was tested in isolated, perfused hearts from rhesus monkeys and mongrel dogs as well as and in intact animals (437) . The studies demonstrated clear antiarrhythmic effect without concomitant change in blood pressure (437) . These studies were conducted using a bee venom batch in which the different components were not entirely separated, and before apamin was known as a specific ion channel inhibitor (136) . It is probably for these reasons that the interesting findings did not lead to follow-up studies for decades.
Sporadic indications of a Ca 2ϩ
-activated K ϩ current were occasionally reported (115), but it was not until 1999 that the first convincing data for cardiac K Ca 2.x channels were presented. Wang et al. (444) (426) . In 2007, the first circumstantial evidence of a relationship between K Ca 2.x channel and arrhythmia was provided (328) . This study demonstrated increased membrane trafficking of K Ca 2.2 channels to pulmonary vein sleeves after burst pacing and a corresponding progressive shortening of action potentials as a consequence of increased I KCa . In 2009, more direct evidence of I KCa association to AF was given (245) . Prolongation of atrial action potentials was observed in K Ca 2.2 knockout mice, and this was associated with a counterintuitive proarrhythmic effect. A likely explanation for the latter could be the sustained and sliding repolarization observed in the knockout mice (triangulation), which is associated with increased propensity for inducible early afterdepolarizations (EAD) under certain conditions. As mentioned, these findings were surprising since prolongation of the atrial effective refractory period is normally considered antiarrhythmic (304) . Later in 2009, a new study failed to show any functional role for cardiac K Ca 2.x channels in rat, dog, and humans under normal physiological conditions, since 100 nM apamin did not affect atrial or ventricular action potential duration in single cardiomyocytes or multicellular preparations, even in conditions with high [Ca 2ϩ ] i (295) . One year later, the first clinical link between K Ca 2.x channels and atrial fibrillation (AF) appeared. A genome-wide association study including 1,355 individuals with lone AF and 12,844 unaffected controls concluded that common gene variants in the area comprising KCNN3 (the gene encoding K Ca 2.3) are connected to AF (118) .
It has further been demonstrated that pharmacological inhibition of I KCa is antiarrhythmic in species such as rat, guinea pig, and rabbit in a model applying isolated perfused hearts. Additional antiarrhythmic effect of K Ca 2.x inhibition was demonstrated in acute burst-induced AF in vivo in rats (102). K Ca 2.x channel inhibition can also prolong the atrial effective refractory period in rats in vivo. This prolongation is associated with an antiarrhythmic effect (396). These effects were additionally confirmed in a more clinically relevant setting using aged spontaneously hypertensive rats (101). These rats exhibited atrial remodeling and thereby increased susceptibility to atrial tachyarrhythmias (75) . The efficacy of K Ca 2.x channel inhibition and the observed antiarrhythmic effect were similar in hypertensiveinduced atrial remodeled rats and in young normotensive controls (101) (FIGURE 3C). Information regarding functional K Ca 2.x channels in remodeled human hearts is sparse. Two articles written in Chinese indicate the presence of apamin-sensitive currents in cardiomyocytes isolated from AF patients in sinus rhythm at the time of the recordings. Furthermore, the apamin-sensitive currents are suggested to be upregulated in persistent AF patients (244, 484) . A new study comparing human atrial tissue from patients in sinus rhythm and in AF shows that the K Ca 2.x channel inhibitor NS8593 prolongs the atrial action potential and refractory period (L. Skibsbye, C. Poulet, J. G. Diness, B. H. Bentzen, L. Yuan, U. Kappert, K. Matschke, E. Wettwer, U. Ravens, M. Grunnet, T. Christ, and T. Jespersen, unpublished data).
Two-pore domain K ϩ channels
Two-pore domain K ϩ (K 2P ) channel proteins are a relatively new addition to the superfamily of potassium channels (333) . These channels are widely expressed and are major determinants of background K ϩ conductance in the cells in which they are present. They set the negative resting potential of eukaryotic cells under a range of normal and pathophysiological conditions (166, 315) . This section will provide a brief introduction to the family of K 2P channels, followed by an account of the possible significance of these channels in human atria.
Fifteen K 2P channel subtypes are known to date, divided into subclasses by homology (FIGURE 4A). Functionally, they lack voltage dependence, but are instead regulated by lipids, temperature, pH, oxygen, membrane stretch, anesthetics, and second messengers (166, 237) . Their widely used trivial names arise from functional attributes such as tandem of "P domains in a weak inward-rectifier K ϩ channel" (TWIK), "TWIK-related channel" (TREK), or "TWIK-related acid-sensitive K ϩ channel" (TASK), to name a few. Functional channels are composed of two subunits, each comprising four transmembrane segments and two pore-forming (P) domains. The structures of K 2P 1.1 and K 2P 4.1 were solved in 2012 (54, 257) (FIGURE 4B). Assembly with traditional K ϩ channel ␤-subunits leading to functional changes has been proposed (217) . The channels are so-called leak or background channels that conduct currents at all phases in the cardiac action potential (FIGURE 2). This conductance ensures the stabilization of the resting membrane potential (E m ) towards the equilibrium potential of potassium. Open K 2P channels will probably both antagonize early afterdepolarizations and play a role in tuning Na V channel availability (16).
The K 2P channels have been described in a variety of species including human, rat, mouse, guinea pig, and dog (reviewed in Ref. 166) . In human hearts, mRNA expression has been shown for K 2P 1.1 (TWIK-1/KCNK1), K 2P 3.1 (TASK-1/ KCNK3), K 2P 4.1 (TRAAK/KCNK4), K 2P 5.1 (TASK-2/ KCNK5), K 2P 15.1 (TASK-5/KCNK15), and K 2P 17.1 (TASK-4/KCNK17) (21, 94, 131, 325, 327) . Most experimental and functional evidence in human heart is reported for K 2P 1.1 and K 2P 3.1, the latter being predominantly expressed in the atrium and the atrioventricular node (117, 131, 250) . Hence, K 2P 3.1 has been added to the list of prominent candidates for developing atria-selective drugs. The following section will give an account of the current knowledge about K 2P 3.1 function in the heart. K 2P 3.1 was originally described by Duprat et al. (109) in 1997. Functional characterization revealed a K ϩ -selective, voltage-independent channel (FIGURE 4C). Furthermore, the channels were highly sensitive to changes in external pH near physiological values (109) and were inhibited by the endocannabinoid anandamide (270) . Meanwhile, more selective tool compounds have been developed (356, 407) . The aromatic carbonamide A293 (Sanofi-Aventis) was shown to inhibit K 2P 3.1 currents at low concentrations (IC 50 222 Ϯ 38 nM in Xenopus laevis oocytes). Furthermore, A293 increased the action potential duration in rat ventricular myocytes, although under nonphysiological conditions (356) . It should be mentioned that a controversy exists regarding the contribution of K 2P 3.1 in rat atria and ventricles. Kim et al. (215) observed a similar expression pattern in the chambers using Northern blot analysis, whereas Liu and Saint (253) reported a more prominent expression in atria compared with ventricles employing quantitative PCR. Evidence for protein expression is sparse due to the lack of specific antibodies in the field (107).
Most of the studies on cardiac K 2P 3.1 function have used mouse cardiomyocytes. In mice, the channel shows a predominantly ventricular expression (107). Taking advantage of a K 2P 3.1 mouse knockout model, Donner et al. (107) showed that K 2P 3.1 (Ϫ/Ϫ) mice display prolongation of the rate-corrected QT interval and reduced heart rat variability. Assessment of time and frequency domains as well as baroreceptor reflex revealed sympathovagal imbalances (107) increasing the impact of sympathetic stimulation in K 2P 3.1( Ϫ / Ϫ ) mice. In a follow-up study, the same group showed that the key electrophysiological parameters such as electrical conduction and refractoriness were unchanged in K 2P 3.1 (Ϫ/Ϫ) mice, yet the heart rate response after premature ventricular contractions was significantly abolished. The authors suggested that the baroreceptor reflex in K 2P 3.1 (Ϫ/Ϫ) is diminished either due to sympathetic predominance or an impaired cardiac parasympathetic activity (342) . In a parallel study employing A293, Decher et al.
(95) also reported that I TASK plays a role in modulation of cardiac action potential duration and that genetic silencing of K 2P 3.1 leads to broadened QRS complexes in a mouse knockout model (95).
The results obtained from the K 2P 3.1 knockout mouse model only partially translate to human physiology given the predominant atrial expression in humans (131, 250 Figure 3 . In red are channels for which mRNA expression has been reported in the human heart (see text for details). B: ribbon representation of the recently resolved K 2P 1.1 structure based on Protein Data Bank ID 3UKM (283) . Transmembrane segments of one subunit are colored (TM1, blue; TM2, purple; TM3, pink; TM4, red). The so-called C-helix located just below the lipid surface is labeled in green; the lipid bilayer is indicated by the black bar. (Picture was generated with Protean 3D, DNASTAR program package.) C: representative patch-clamp recordings of CHO-K1 cells transiently expressing K 2P 3.1, or mock-transfected cells. Current was recorded during 500-ms voltage-clamp pulses from Ϫ120 to 100 mV in 20-mV steps from a holding potential of Ϫ80 mV. Limberg et al. (250) investigated the role of K 2P 3.1 channels in human atria. They showed that a current carried by K 2P 3.1, I TASK , accounts for ϳ40% of background current in human atrial myocytes isolated from healthy humans. Furthermore, applying a mathematical model adapted to atrial action potential, the authors showed that changes in I TASK may alter the duration of the atrial action potential (250) .
The latter observation supports the notion that K 2P 3.1 may be a valuable target candidate for the development of drugs against atrial fibrillation. Inhibition of K 2P 3.1 is speculated to prolong action potential duration and effective refractory period and to suppress atrial arrhythmias. Recently, several antiarrhythmic drugs have been applied to K 2P 3.1 channels. Carvedilol inhibited heterologously expressed K 2P 3.1 with IC 50 ϭ 0.83 M in mammalian Chinese hamster ovary (CHO) cells (405) . The class III antiarrhythmic drug amiodarone was shown to inhibit K 2P 3.1 channels in Xenopus laevis oocytes (IC 50 ϭ 0.4 M) without changing rectification properties (139) . Also dronedarone inhibits K 2P 3.1 channels in both Xenopus laevis oocytes (IC 50 ϭ 18.7 M) and CHO cells (IC 50 ϭ 5.2 M) (379). A more specific drug, A1899 (Aventis), was recently reported. The compound inhibited K 2P 3.1 as an open-channel blocker with an IC 50 ϭ 7 nM in CHO cells, and bound to the closely related K 2P 9.1 with a 10-fold lower affinity. Furthermore, A1899 did not affect a large panel of other channels expressed in human cardiomyocytes (407) . The recent publication of the human K 2P 1.1 crystal structure could enable the development of specific drugs (257) .
Despite the apparent role of K 2P channels for setting the resting membrane potential and participating in repolarization, only a few reports exist on disease-associated mutations in these channels. Lafrenière et al. (229) reported a dominant-negative mutation in K 2P 18.1 (TRESK/KCNK18) linked to a form of familial migraine. An abstract written in German alludes to a gain-of-function K 2P 17.1 (TASK-4/KCNK17) variant associated with conduction defects (127).
Of note, Barbuti et al. (27) described a role for K 2P 3.1 channels in the arrhythmic effects of inflammatory phospholipid platelet-activating factor (PAF) in mice. PAF is released upon reperfusion after ischemic events and triggers arrhythmia (262) . Barbuti et al. (27) showed that PAF action induced spontaneous beats, EADs, and prolonged depolarization similar to previous observations in canine cardiomyocytes. These effects involved PKC-dependent block of K 2P 3.1 (27). The same group recently reported an association between K 2P 3.1 inhibition with atrial fibrillation in a canine model of peri-operative AF (113). However, the study did not irrevocably show whether K 2P 3.1 inhibition contributed to arrhythmogenesis or whether it was secondary to AF induction in this specific animal model (173) .
Very recently, impaired K 2P 3.1 function was postulated as an arrhythmogenic substrate (247) . Transient knockdown of K 2P 3.1 expression affected atrial size in a zebrafish model. Furthermore, reduced K 2P 3.1 current prolonged atrial action potential duration in cardiac action potential modeling, which was potentiated by reciprocal changes in activity of other ion channel currents (247) .
In addition, it should be kept in mind that K 2P 3.1 function has also been related to other pathophysiological conditions such as ischemia, cancer development, inflammation and epilepsy (reviewed in Ref. 44). Hence, therapeutic value has to be carefully considered given the wide distribution of these channels in tissues other than the heart. Although K 2P 3.1 channels are attractive candidates for the development of atrial-specific drugs, further studies are warranted to elucidate whether K 2P 3.1 inhibitors are antiarrhythmic or proarrhythmic.
C. Striking the Wrong Note: Genetic Variation Causing Arrhythmia
Several ventricular and supraventricular arrhythmias such as long and short QT syndromes (LQTS, SQTS), Brugada syndrome (BrS), Andersen's syndrome, and AF have been associated with impaired potassium channel function (reviewed in Ref. 311 ). Disease-associated mutations in the genes encoding the repolarizing potassium channels of the heart have been instrumental in understanding the channels' physiological function and their role in pathophysiological conditions. TABLE 2 gives an overview of potassium channel subunits associated with arrhythmia.
In the case of ventricular arrhythmias, loss-of-function of potassium conductance leads to action potential prolongation and syndromes such as the LQTS. Vice versa, gain-of-function results in shortening action potential duration and SQTS (174) . Supraventricular arrhythmias such as AF show a more complex pattern as both loss-offunction and gain-of-function mutations in a single potassium channel have been described (e.g., Ref. 79), as well as mutations showing a mixed phenotype of AF and QT prolongation (265) . AF as well as LQTS are generally considered to be driven by triggered activity and electrical reentry. In both conditions, action potential prolongation tends to increase the triggered activity, whereas action potential shortening, as it is observed in AF and in SQTS, promotes reentry.
In general, the heart rate corrected QT interval (QTc) is considered to be a measure of ventricular repolarization. Its prolongation has been associated with an increased risk of sudden cardiac death (494) , although its predictive value for ventricular arrhythmia is debated and the concept of TRIaD (triangulation, reverse use depen-dence, instability and dispersion) has been suggested (184, 186, 187) . However, there is increasing evidence that prolongation of the mean QT interval is associated with AF (330) . A recent study including digital ECGs from more than 300,000 persons confirmed that the QTc interval length is a predictive parameter for the susceptibility of AF (308) . Of note, both shortened and in particular prolonged QTc interval duration are risk factors for AF (308) . This association was strongest for lone AF cases, a condition in which other predisposing diseases such as hypertension, diabetes, ischemic, and/or valvular heart diseases are absent (66, 67) . The study indicates that QTc prolongation is an inherent characteristic of an individual's cardiac electrophysiology and that prolonged QTc can predispose to AF (308) . Vice versa, Johnson et al. (199) have previously shown a prevalence of early-onset atrial fibrillation in congenital LQTS. Hence, ventricular and atrial arrhythmia phenotypes seem to overlap, although knowledge about the mechanisms on the cellular and molecular levels is only slowly accumulating.
Major challenges in elucidating these mechanisms are the often observed 1) low penetrance in families and 2) variable expressivity in mutation carriers. As illustrated in FIGURE 5, penetrance describes the extent to which all mutation carriers within a family develop the clinical symptoms of the respective disease. Variable expressivity designates the degree to which individuals with the same genotype express a certain phenotype. Congenital LQTS is a paradigm for such an arrhythmia with incomplete penetrance and variable expressivity (reviewed in Ref. 141) . It has been recognized that additional factors contribute to the manifestation of the arrhythmia and the observable symptoms. The impact of factors such as gender, age, seasonal changes, circadian rhythm, and triggers such as auditory stimuli or exercise, or physiological challenges such as hypokalemia have been reported (42, 89, 152, 165, 227, 290, 414, 486) . Beyond environmental modifiers, the presence of additional genetic modifiers is well-recognized. Both compound heterozygosity and digenic heterozygosity have been described (381, 453) . A recent study has shown that LQTS patients with multiple If more than two reports exist, the original reference is provided together with a link to a mutation database or relevant review.
mutations in the known LQT genes had a higher rate of life-threatening cardiac events (291) . Yet, a general picture emerges that shifts the focus from monogenic inheritance, where very rare variants with a frequency Ͻ0.1% in the general population are considered disease causing, to oligogenic (0.1% to Ͻ 5%) or polygenic (common variants Ͼ5%) inheritance patterns. It seems that the more frequent the genetic variant, the lower its effect on ion channel function and hence cardiac rhythm. Yet, these nonsynonymous variants of potassium channel genes also present in the healthy population may act as modulators of the cardiac action potential and as a "second hit" when the individual faces physiological challenges (reviewed in Ref. 141 ).
Several recent genome-wide association studies (GWAS) followed the hypothesis that traits such as heart rate or QTc interval used as markers for arrhythmia are associated with single-nucleotide polymorphisms (SNPs) (reviewed in Refs. 282, 394 ). The analysis of many common genetic variants in different individuals led to the identification of a number of candidate genes such as KCNN3 encoding K Ca 2.3 (SK3) channels (118) . Although this association has been supported by other studies (70, 320) , no disease-causing mutations in the exons or splice sites of KCNN3 have been reported to date.
Noteworthy, the increasing availability of genomic data is challenging the concept of channelopathies as monogenic disease as well as aiding understanding of the basis of arrhythmia. Analyses of continuously updated exome data provided by the NHLI GO Exome Sequencing Project (ESP) currently holding data from 6500 individuals (119a) revealed that many previously disease-associated mutations are in fact variants that occur frequently in the general population (14, 363) . Hence, these variants might not be the underlying cause of the disease.
Solid conclusions regarding a causative link between genomic variant and disease require a combination of 1) detailed analysis of frequency in the general population, 2) algorithms to predict the pathogenic effects of the variant (reviewed in Ref. 420), 3) verification of findings in independent cohorts, 4) often laborious and time-consuming experimental knowledge using suitable in vitro assays, and 5) evaluation of cosegregation in families. The latter is often hampered by small family sizes, lack of Mendelian inheritance, lack of penetrance, and/or variable expressivity.
A wealth of publications on variants and mutations, functional data, and possible new players important for cardiac rhythm are continuously being released, which challenges the attempts to see the larger picture of the disease-causing processes. For a decade, Napolitano and Wilson (298) have put tremendous effort into maintaining a large annotated database listing mutations and common variants associated with cardiac arrhythmia. Owing to the complexity of the genetic traits, the availability of genomic data, and the ever improving systems for functional characterization, it is likely that the field will benefit from continuous efforts to collect all available data, including negative findings, in such an arrhythmia database maintained by the scientific community. Such information would be valuable as a guide to understanding the physiological/pathophysiological mechanisms of arrhythmia, as well as for risk stratification of affected family members.
D. Tuning the Instruments
The delicate act of keeping the heart beat stable under all conditions is quite sensitive to changes in the function of the key ion channels. The expression and activity of the channels may vary significantly as a consequence of posttranscriptional and epigenetic changes. Furthermore, the channel function is also drastically influenced by the proteins' exact subcellular localization within cardiac myocytes; the complexes they form with accessory subunits, kinases, and phosphatases; and posttranslational modifications. As elaborated above, channel function can change due to mutations, yet also due to electrical remodeling and presence of drugs. Below we will give a short account of some of these important mechanisms that influence the function of the channel on its way from the gene in the nucleus to the surface-expressed protein, and their significance for cardiac repolarization. FIGURE 6 gives a summarized picture of the outlined regulatory mechanisms.
Posttranscriptional mechanisms
Alternative splicing of mRNA transcripts has been described for most of the repolarizing potassium channels of the heart. Accordingly, several isoforms with different functional phenotypes exist (22, 200, 223, 327, 402, 404, 460, 469, 499) . The alternative splicing increases the redundancy of the channels, but also helps to diversify the function of the multimeric proteins. Some isoforms are highly expressed in the heart but, surprisingly, exert dominantnegative effect on channel function when coexpressed in heterologous expression systems (201, 228, 287) . Differential expression of K V 7.1 isoforms K V 7.1-iso1 and K V 7.1-iso2 across the human ventricular wall has been suggested to contribute to action potential heterogeneity (338). Whereas the total expression level in the endocardial, midmyocardial, and epicardial layers was similar, the proportion of the dominant-negative K V 7.1-iso2 was higher in midmyocardial tissue. Mimicking the experimentally determined ratios in heterologous expression systems indicated a drastically reduced midmyocardial I Ks compared with that in the epicardium. (338) . Consequently, endo-and epicardial myocytes are reported to have shorter action potentials (57, 251). Recently, Lee et al. (234) determined the effect of amiloride on the ratio of these K V 7.1 isoforms in canine endocardial, midmyocardial, and epicardial ventricular myocytes. Whereas the drug led to decreased expression levels of K V 7.1-iso1 in endocardial and epicardial layers, K V 7.1-iso1 was increased in midmyocardium. The authors further investigated the impact of these changes on action potential duration using simulations of human ventricular action potentials. Their results supported the earlier findings that transmural differences in I Ks density might be explained by the ratio of the two isoforms (234, 338) and indicated that amiloride may lead to a reduction of the transmural I Ks gradient (234) .
Assembly of different K V 11.1 isoforms in the native channel complex influences the kinetics (233) and pharmacological sensitivity (231) and has been implicated in arrhythmia (372, 422) . Accordingly, a number of splice-site mutations have been associated with arrhythmia (298).
An additional regulatory mechanism, nonsense-mediated mRNA decay (NMD), has been described for K V 11.1 channels. NMD is an RNA surveillance mechanism that selectively degrades mRNA transcripts that have in-frame premature termination codons. Nonsense mutations have been implicated in human disease (289) , and NMD is thought to serve as a "cellular vacuum cleaner" that protects the cell from the potentially harmful effects of truncated proteins by eliminating mRNAs with premature termination codons. NMD occurs when translation terminates 50 -55 nucleotides upstream of the 3'-most exon-exon junction (33). Gong and co-workers investigated LQT2 nonsense mutations that showed a decrease in mutant mRNAs by NMD, thereby altering the amount of mRNA available for subsequent K V 11.1 protein generation. It was suggested that the degradation of premature termination codons containing mRNA transcripts by NMD represents a new class of LQT2 pathogenic mechanism (148, 149, 410, 487 ). Yet of all the channel proteins involved in cardiac excitability described above, this mechanism has been exclusively described for K V 11.1 channels.
Traditionally, the field has focused on the protein encoding sequence of DNA and paid only scant attention to 5'-or 3'-untranslated regions (UTR). This changed with the discovery of so-called microRNAs. These small noncoding RNAs are part of the epigenetic control of gene expression that also encompasses DNA methylation and histone modifications (143) . The binding of miRNAs to the 3'-UTR of their targets can lead to degradation of target mRNAs or repression of target mRNA translation. A number of cardiovascular-specific miRNAs have been described (reviewed in Ref. 45). A very interesting feature is the fact that miRNAs may regulate multiple targets simultaneously, which allows for complex and cooperative regulation of several channel proteins whose functions are tightly connected. Also, several miRNAs can bind to the same target, which increases the level of regulatory control. Although the field is only emerging, several miRNAs have been linked to the regulation of the cardiac repolarizing potassium channels (216) . Hence, changed miRNAs levels in disease conditions may have an impact on cardiac excitability. Examples are the downregulation of miR-1 in atrial fibrillation leading to increased I K1 currents (140) or the upregulation of miR-301a in a diabetic mouse model leading to Targeting signals in the protein may guide the membrane protein to a specific location within the cardiomyocyte, e.g., t tubules or intercalated discs. The potassium ␣-subunit can interact with accessory subunits and undergo additional posttranslational modifications such as phosphorylation (P) and ubiquitination (Ub). Ubiquitinated proteins are endocytosed and degraded in the proteasome (via lysosomes). Alternatively, the channel can be recycled to the membrane in recycling vesicles (not shown).
decreased I to (332) . An overview of known miRNAs affecting cardiac potassium currents is given in Adding another level of complexity, Amin et al. (12) reported that common variants in the 3'-UTR of the KCNQ1 gene encoding K V 7.1 modified disease severity in LQTS patients in an allele-specific manner. As K V 7.1 channels are composed of tetramers, in a heterozygous mutation carrier channels will be formed from two healthy and two mutant subunits, provided that wild-type and mutant alleles are expressed equally well. The authors found several SNPs in the 3'-UTR of the KCNQ1 gene. With the assumption that the SNPs exert no effect on expression, the balance between normal and mutant subunits within each channel should be equal. However, the authors suggested a model in which the subunits carrying the disease-modifying SNPs were suppressed, which would affect the balance between wild-type and mutant channel subunits. Such suppression could be mediated by miRNAs that bind to consensus sites in the 3'-UTR. Depending on which nucleotide sequence favors the binding of miRNAs, then the balance of wild-type and mutant subunits relies on whether the "suppressive" SNP variants reside on the normal or mutant allele. Accordingly, an increased expression of the mutant allele would enhance the disease phenotype of the patient, while an increased expression of the wild-type allele could possibly result in an asymptomatic phenotype (12) .
Further research exploring these outline mechanisms will hopefully shed additional light on the determinants of low penetrance and variable expressivity in arrhythmia research.
Posttranslational regulation of potassium channels in protein complexes
Potassium channels are often pictured as isolated membrane proteins, but it is well recognized that they are part of large complexes. They form multimolecular complexes with each other as well as with accessory subunits, anchoring proteins, and regulatory kinases and phosphatases. The association with non-pore-forming proteins, so-called ␤-subunits, helps to regulate and modify the function of the ␣-subunit, likely in a temporal and spatial manner. A number of excellent recent review articles have covered the composition and regulation by accessory subunits for the protein complexes underlying I to , I Kur , I KAch , I Kr , and I Ks currents (268, 311, 359, 433, 464) .
Of all the cardiac ion channel complexes, the I Ks channel has probably received the most attention due to its regulation by the KCNE family of ␤-subunits. The interaction with KCNE1 (29, 376) leads to dramatic changes in biophysical properties such as a major increase of macroscopic current, slowed activation, and shift of the voltage dependence of activation to more depolarized potential (reviewed in Ref. 464) . The exact mode of interaction between these subunits and their stoichiometry has been intensively studied and is still a matter of debate. The interaction seems to be dynamic with variable stoichiometry and interaction sites (reviewed in Ref. 464 ). In addition to KCNE1, the ␣-subunit is able to interact with all five members of the KCNE channel family in heterologous expression systems (197 In 2012, Milstein et al. (285) used a multipronged approach to show a large macromolecular complex involving both K ir 2.1 and Na V 1.5 channels. They thereby revealed an extraordinarily tight connection between the I K1 current controlling the resting membrane potential and I Na , whose availability, effect on cell excitability, action potential duration, and velocity of impulse propagation are governed by the membrane potential set by I K1 (285) . Noteworthy, the postsynaptic density, discs large and zonula occludens-1 (PDZ) domain protein SAP97 is a component of this macromolecular complex (285) . The same anchoring protein has previously been shown to interact with K V 1.5 in both heterologous expression systems (292) and cardiomyocytes, where it seems to stabilize the channels in the plasma membrane (72) . This opens up for the possibility of even larger macromolecular complexes also involving I Kur channels.
In addition, these multiprotein complexes link membrane proteins to intracellular proteins and contain components of the cytoskeleton and extracellular matrix proteins. Furthermore, cardiac myocytes are polarized cells with most ion channels localized at specific subdomains such as the t-tubular invaginations or intercalated disks. Hence, highly regulated trafficking and targeting mechanisms are crucial to achieving these specific locations. The mechanism and the current view on where the potassium channel complexes are located within the surface membrane of cardiomyocytes are reviewed in Reference 26.
Protein activity is not only controlled by the rates of protein biosynthesis and protein degradation, but also by specific and selective covalent processing, i.e., posttranslational modification (PTM) such as phosphorylation, which modulates molecular interactions, protein localization, and stability. TABLE 4 lists the current knowledge on PTMs for the major repolarizing currents of the heart.
These modifications may provide an important feedback mechanism for regulating the number of functional complexes upon external stimuli from, e.g., hormones and the autonomic nervous system, which will significantly influence cardiac signaling. The greater our understanding of the signaling pathways, the more complex the picture may become. Several studies have shown that common genetic variants in the components that modulate potassium channel function such as G protein-coupled receptors or kinases may have an influence on cardiac signaling. SNPs in the genes encoding ␣2 and ␤1 adrenergic receptors, ADRA2C and ADRB1, respectively, have been linked to the LQTS disease phenotype (reviewed in Ref. 141 ). Furthermore, a recent study on chronic AF in humans showed a chamberspecific upregulation of ␤1 adrenergic receptors, which led to dramatic effects on several repolarizing currents, foremost I Ks (150) .
Other (19) were the first to establish a link between the age, gender, and heart rate corrected QT-interval with SNPs in the gene encoding nitric oxide synthase 1 adapter protein (NOS1AP, also known as CAPON) (19). The SNP rs10494366 located in the upstream region of the coding region achieved genome-wide significance. This finding has been replicated in several large independent populations of both European ancestry and other ethnicities. In those studies, several additional NOS1AP SNPs were found to be significantly linked to the QTc interval (1, 18, 114, 274, 306, 343, 352) . Noteworthy, NOS1AP SNPs reached higher significance compared with SNPs in genes known to be causes of LQTS and SQTS (306, 343) . Furthermore, NOS1AP has been linked to sudden cardiac death (205, 326) .
Analyzing the protein complexes and their regulation in the cellular network will help our understanding of the complex regulation of cardiac excitability.
III. MECHANISMS AND ETIOLOGY OF ARRHYTHMIAS
Arrhythmia in its broadest sense describes every type of abnormal heart rhythm ranging from gentle transient palpitations to devastating fibrillations. Ultimately, fibrillation in the ventricles can result in sudden cardiac arrest. A subdivision of arrhythmias encompasses bradycardia and tachycardia, representing too slow or too rapid heart rates, respectively. Heart rates are species dependent, and humans are considered bradycardiac when having fewer than 60 bpm and tachycardic with more than 100 bpm. In brady-or tachycardia the individual can either have a regular rhythm triggered by the sinus node (sinus rhythm), or an irregular arrhythmia governed by other mechanisms. In AF, the atrial rhythm is Ͼ200 bpm. While not lethal, it is associated with thromboembolic events and an increased risk of cardiac death in a longer perspective (36). This increased morbidity and mortality is the result of the reduced ejection fraction during tachycardia and blood stasis in the fibrillating atria increasing the propensity of thrombosis and stroke (461) . Ventricular arrhythmias are significantly more serious as they directly influence the pumping capacity of the heart. A ventricular tachyarrhythmia can be both monomorphic and polymorphic in origin and can eventually develop into fibrillation. In ventricular fibrillation, the electrical activity of the cardiac cells occurs in a completely uncoordinated manner and pumping ceases.
From a mechanistic perspective, tachyarrhythmic events are obligate depending on two phenomena: a triggering event for initiation and a substrate for sustainability. In the following, we give a thorough overview of triggers and substrates. This includes an introduction to the spiral wave and CARDIAC POTASSIUM CHANNELS AND ARRHYTHMIA Only direct posttranslational modifications that have been reported in either mammalian cell systems or cardiac tissue are listed. References are given for the first report on the respective modification. If known, the amino acid position referring to full-length protein and enzyme are given. Note that some regulatory pathways act via accessory subunits not included in this list. CaMK, calmodulin-dependent kinase; EGFR, epidermal growth factor receptor; gp, guinea pig; h, human; Nedd4, neuronal precursor cell-expressed developmentally downregulated 4; PAT, palmitoyl acyltransferase; PKA, protein kinase A; PKC, protein kinase C; PP1, protein phosphatase 1; PTK, phosphotyrosine kinase; p90RSK, p90 ribosomal S6 kinase; r, rat; RhoK, Rho kinase; USP2, ubiquitin-specific protease 2.
leading circle theories explaining reentry-based arrhythmias to understand the role of the repolarizing currents in these arrhythmias.
A. Triggers of Arrhythmias
The initiation of an arrhythmia requires a triggering event.
Abnormal focal automaticity constitutes a typical trigger. Several areas of the heart have the intrinsic capability for automaticity or pacemaker activity, but under normal circumstances the sinoatrial node has the fastest pacemaker rate and will therefore be the area that determines the heart rate. Impulse generation in areas outside the sinoatrial or atrioventricular nodes is called abnormal automaticity, and the abnormal pacing site is called an ectopic focus. Several factors can increase the risk of abnormal automaticity, such as increased sympathetic drive, acute myocardial ischemia, or electrical remodeling leading to changed ion channel distribution (51, 358). Areas around the left and right pulmonary veins are especially sensitive to triggering events (167) . The increased likelihood of focal (nonreentrant) arrhythmias around pulmonary veins is explained by several factors: specialized cells with pacemaker activity are located here, and the resting membrane potential is more depolarized as a consequence of reduced I K1 current (111, 238). Abnormal focal activity can also be initiated by early afterdepolarizations (EADs), which are inappropriate secondary depolarizations taking place during the normal repolarization phase of the cardiac action potential (phase 3) (FIGURE 7). EADs are primarily due to reactivation of the voltage-gated Ca V 1.2 channels (L-type Ca 2ϩ channels). These channels are activated during the initial depolarization of the action potential (phase 0) and will subsequently undergo inactivation in a time-, voltage-, and Ca 2ϩ -dependent manner. The inactivation is released by the hyperpolarization of the membrane potential and reduction in [Ca 2ϩ ] i in phase 3. If release from inactivation takes place while the membrane potential is still sufficiently depolarized to allow for activation of the Ca V 1.2 channels, the result is inappropriate reopening that will prompt an EAD (392, 474, 488) . The critical time interval during repolarization that allows for reactivation of the Ca V 1.2 channels is recognized as the "vulnerable window." This normally lies from 30 to 90% of full repolarization of the action potential (APD 30 -APD 90 ). EADs typically originate in ventricular tissue zones with extended action potentials, such as the Purkinje system, but can also be observed in atrial tissue as triggers for atrial fibrillation (58, 378, 473) . It is worth mentioning that it is not simply the action potential duration per se that governs whether an EAD might commence. The exact morphology of the action potential in the repolarizing phase 3 is probably more important (184) . Delayed repolarization seen as a prolongation of the APD 30 -APD 90 interval will increase triangulation of action potentials and thereby also the time interval for the vulnerable window. This augments the probability for EADs. A typical situation for EAD-triggered arrhythmias in both atria and ventricles is the LQTS (199) .
Another source of abnormal focal activity is delayed afterdepolarizations (DADs) (FIGURE 7) . A DAD describes inappropriate depolarizations in the time interval from complete repolarization of an action potential to the upstroke of a subsequent action potential, i.e., during the diastolic interval or phase 4. The mechanistic understanding of DADs relies on inappropriate activity of the Na ϩ /Ca 2ϩ exchanger. This cotransporter has a stoichiometry of 3 Na ϩ exchanged for 1 Ca 
, which generates a net inward transport of positive ions resulting in a depolarizing current. The effect of this current can normally be counteracted by the large resting K ϩ conductances. In situations with excessive intracellular Ca 2ϩ load, this electrogenic exchange generates a depolarization recognized as a DAD (183, 295, 434, 503) . Intracellular Ca 2ϩ overload can be subsequent to Ca 2ϩ leak from mutant ryanodine receptors (RyR) in the sarcoplasmic reticulum, which can result in catecholaminergic polymorphic ventricular tachycardia and concomitant fibrillation (347) . Hyperphosphorylation of RyR as a consequence of increased sympathetic drive can also provoke phase 4 Ca 2ϩ overload and DADs (106). Congestive heart failure is another source of Ca 2ϩ overload and fibrillation (481).
B. Substrates for Reentry-Based Arrhythmias
In order for sustained arrhythmias to occur, the triggering event must subsequently initiate a self-sustained episode of action potential propagation. A change in the conduction properties of the cardiac tissue is a prerequisite for such an activity, and that is called a substrate. Substrates can be anatomical obstacles in nature or based on electrophysiological heterogeneity. The shared denominator is that independently of its origin, the substrate will allow for sustained excitation and propagation of action potentials. Such a situation can arise if the tissue is allowed to regain excitability before the propagating wave of electrical signals meets its starting point. Situations that will prompt this are slow propagation of electrical signals or if the signal has to travel a long path to again reach its starting point. The resulting self-sustained and uninterrupted propagation of electrical signals is denoted a reentry-based arrhythmia. A more detailed description of the nature of different substrates is given in the section describing remodeling.
The concept of reentry in the context of fibrillation has been known for more than a century, as have the ideas about unidirectional blocks and the involvement of obstacles or substrates in the development of arrhythmia (FIGURE 8).
Almost 50 years ago, a mathematical description and the first modeling of functional reentry was provided, including the notion that the substrate did not necessarily have to be of anatomical origin (286, 303) . A historical overview in combination with an excellent description of theories for reentry-based arrhythmias is given by Comtois et al. (81) .
On the background of these classical experiments, two different theories have been developed to explain reentrybased arrhythmias: the leading circle and spiral wave theories. A brief introduction to both phenomena is useful to facilitate the understanding of the role of ion channels in re-entry mechanisms.
The leading circle
Allessi and co-workers (8 -11) were the first to demonstrate and describe functional reentry based on experimental evidence, from which they developed the leading circle model: "The smallest possible pathway in which the impulse can continue to circulate is the circuit in which the stimulating efficacy of the circulating wavefront is just enough to excite the tissue ahead which is still in its relative refractory phase." The principle is illustrated in FIGURE 9A. In the situation of an unidirectional block (illustrated by the gray square), the leading circle can be defined as the smallest possible circle of continuous propagating electrical activity (illustrated by the heavy black arrow), which is exactly sufficient in length to reach is original point of initiation at the time point when absolute refractoriness has ended and reexcitation can be evoked. It follows that a smaller circle will reach the starting point at a time point when absolute refractoriness still prevails, hence making reexcitation impossible, so the reentry will terminate. Impulses traveling longer circles will have longer turn-around time, and hence the reentry activity will be dominated by the shortest possible circle that therefore receives the name, the leading circle. The length of such a leading circle is called the wavelength (WL), and this is equal to the product of the effective refractory period (ERP) and conduction velocity (CV) as WL ϭ ERP ϫ CV. A reduced wavelength will mean that In normal tissue, the electrical signals travel down each branch with equal velocity. If the two branches are connected, the signals will encounter refractory tissue and will not progress. Yet, if one branch exhibits a unidirectional block (indicated in red) (2), the electrical signal will travel down only one branch (1) . If the signal enters the common branch at a time where it is not refractory, retrograde signaling (3) and re-excitation can occur resulting in self-sustained propagation (4).
more circles can be included within a given tissue area, thereby increasing the risk of reentry-based arrhythmias, so a reduction in WL is considered proarrhythmic. By the same argument, a prolongation of the WL will be antiarrhythmic. This is the basic principle accounting for the efficacy of classic class III antiarrhythmics. These drugs prolong action potential duration by inhibition of the K ϩ channels responsible for phase 3 repolarization (108, 389). ERP is consequently increased, and provided that CV is unchanged, it leads to increased WL and diminished risk of reentry (FIGURE 9) (301) . This principle is particularly valid for atrial arrhythmias, whereas in ventricles it has unambiguously been shown that K ϩ channel inhibition can also lead to an increased heterogeneity in the ventricular action potential duration, and this is profibrillatory (17, 82, 353 ). In the context of AF, it should also be mentioned that structural remodeling leading to atrial enlargement or dilatation is considered proarrhythmic, the reason being that increased tissue area is equivalent to a relative reduction in WL. Physical or electrical atrial remodeling can be caused by valve stenosis, insufficiency, congestive heart failure, or tachycardia and is an important clinical cause of sustained AF (176, 390) . The leading circle theory is fascinating in its simplicity and is good for illustrating class III antiarrhythmic efficacy, but from a biophysical perspective, it is probably not the most accurate representation of re-entry based arrhythmias.
The spiral wave
With the development of high-resolution mapping studies and more advanced in silico modeling, it has become evident that reentry explained by spiral waves is more likely to reveal the true nature of reentry-based arrhythmias compared with the leading circle theory. This includes observed properties such as dynamic core behavior, electrogenic source-sink relations, electrotonic interactions, and the predicted response to Na ϩ channel inhibition (class I antiarrhythmics) (81, 91, 286, 457) .
The concept of a spiral wave has been developed and described by a number of groups (93, 219, 340, 395, 455). In its most simple form, a spiral wave can be described as a continuous, rapid movement of electrical signals that rotates around a central core. An important difference between the leading circle and the spiral wave is that the latter operates with a curved wave front as shown in FIGURE 9. Depolarizing activity originates from a central core, marked by the largest and more heavily dotted circle in FIGURE 9B, and propagates away from the center. The curved depolarization wavefront is depicted by the solid black line and direction of propagation indicated by the black arrows. Since the depolarizing part of the wave is radiating outward, each cell will have to excite more than one cell when moving away from the core. This generates a source to sink mismatch and consequently decreases propagation velocity. The depolarization will naturally be followed by a repolar- ization front represented by the solid red line. As a consequence of the curvature of the wave, there is a point or area where the depolarizing and repolarizing fronts meet. This point is termed the phase singularity of the spiral wave and is represented by the inner dashed circle (FIGURE 9B) (81) . In the leading circle, the central core is believed to be nonexcitable due to refractoriness obtained from centripetal wavelets originating from the leading circle (represented by black arrows pointing inward in FIGURE 9A ). This notion was originally based on measuring very short action potentials with reduced amplitude in the central core (11) . Later studies showed that the true nature of the core is better represented by the spiral wave theory describing an excitable but nonexcited core (188, 192, 206) . From a biophysical perspective, this is explained by the phase singularity that represents such an excitable area of tissue, which is, however, nonexcited due to the nature and rotation of the spiral wave. Outside this area of phase singularity, there will be a larger area (represented by the outer dashed circle in FIGURE 9B) characterized by electrotonic activity, i.e., a movement of depolarization that can spread from cell to cell but does not have sufficient amplitude to reach the threshold for activation of new action potentials. This area of passive activity will serve as a current sink for surrounding tissue. As a consequence of cell-cell coupling, there is a reduction in action potential duration in the surrounding tissue that serves as a source for the passive central sink area. The principle is illustrated in FIGURE 9, C AND D. These electrotonic properties and the faster repolarization as a consequence of the shortened action potential duration have been demonstrated to be pro-arrhythmic by stabilizing rotor behavior and preventing wave breaks (74, 92). The combined effect of core size, wave curvature, and electrotonic properties will have important impact on the wave tip dynamics. A final important notion about the spiral wave theory is the inclusiveness of meandering, i.e., the turning and winding movement of the wave front through the cardiac tissue. To a large degree, the exact trajectory of a given spiral wave will depend on the wave tip dynamics (123, 207, 458) . Generally, a very stable core with a minimum of meandering is considered proarrhythmic (213) . This is explained by the reduced chance for moving into refractory tissue and thereby the decreased likelihood of wave-breaks that can terminate the re-entry.
Implications for modes of drug action
An important reality check on the two reentry theories of leading circle versus spiral wave is how they encompass the effects of antiarrhythmic compounds. The leading circle easily explains how the class III compounds inhibiting repolarizing K ϩ currents cause an increased ERP and concomitant increase in WL (WL ϭ ERP ϫ CV), which according to the theory should be antiarrhythmic. When explaining the efficacy of K ϩ channel inhibitors on the basis of spiral wave reentry, the situation is more complex, although this model also predicts an antiarrhythmic effect. The exact outcome will, however, depend on which type of K ϩ current is targeted. In general, reduced action potential duration will tend to accelerate and thereby stabilize rotors (31). From this perspective, an antiarrhythmic effect is expected when blocking K ϩ currents, especially when targeting I K1 (373) . Other antiarrhythmic effects of K ϩ channel inhibition are explained by an increase in the core area and meandering (31). Yet, in principle, K ϩ current inhibition can also result in formation of additional spiral waves, especially in ventricular tissue. In situations with sufficient excitable tissue, this could lead to fibrillatory activity (134, 362, 412) .
In attempts to explain the efficacy of class I compounds represented by Na ϩ channel inhibitors, the leading circle theory falls short. Na ϩ channel inhibitors are divided into class Ia, Ib, or Ic according to their effects on Na ϩ channel kinetics being intermediate, fast, or slow, respectively, and on the different effects on action potential morphology (284, 318) . All classes will decrease CV, and class Ib will further decrease ERP. Recalling WL ϭ ERP ϫ CV, it follows that Na ϩ channel inhibitors will decrease WL via both parameters, and thereby should be proarrhythmic. Although all antiarrhythmics can comprise proarrhythmic properties under certain circumstances, the overall antiarrhythmic effects of class I compounds seem to be in opposition to the leading circle description of reentry. In contrast, antiarrhythmic effects of class I compounds are easily explained from the spiral wave perspective. Na ϩ channel inhibition is expected to increase core size and meandering and to decrease curvature (211, 221) . Na ϩ channel inhibition will also diminish the source-to-sink mismatch in the core area of the spiral wave. Altogether these effects should terminate reentry-based arrhythmias (81) . It should be noticed that the concepts presented above primarily apply to atrial tissue. In ventricles, the larger muscle mass complicates the nature of reentry, as will be discussed in the section on ventricular fibrillation.
Finally, it should be mentioned that during the last 60 years, the spiral wave and leading circle theories have gained most attention for explaining the principles of multiple circuit reentry. There is, however, also more recent experimental evidence to support single reentry circles, mainly in the areas of mitral valves and pulmonary veins as the foundation of especially atrial fibrillation. Depending on the conditions, single reentry, multiple reentry, and ectopic foci can all impact reentry-based arrhythmias to various degrees (301).
C. Atrial and Ventricular Fibrillation
Having introduced triggers, substrates, and unidirectional block as prerequisites for the development of fibrillation, in this section we give a short introduction to the etiology of atrial and ventricular fibrillation.
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AF is by far the most common sustained cardiac arrhythmia and accounts for approximately one-third of hospitalizations related to heart rhythm disturbances (129) . The overall lifetime risk for getting AF is ϳ25% in the general population (254) . In a historical perspective, AF was first described in 1906, and characterized as rapid uncoordinated electrical activation of the atria (130) . Several classification systems are now used to describe various forms of AF. These include categories such as acute, paroxysmal, intermittent, constant, chronic, persistent, and permanent. When a patient encounters two or more episodes, the AF is considered recurrent. Should the recurrent AF terminate and revert to sinus rhythm spontaneously within a week, the designation paroxysmal is used. If AF continues for longer than 7 days, it is categorized as persistent. Finally, AF can become permanent. This is a clinical definition for ongoing AF resistant to cardioversion or for very long-term AF for which cardioversion has not been attempted.
Although not devastating per se, AF can significantly influence life quality, and the disease is associated with a longterm increased risk of death (204) . The uncoordinated movements of the atria during AF result in impaired ventricular filling and blood stasis and thrombosis in the atrial appendices. The condition predisposes to heart failure and thromboembolic stroke, respectively (443, 461) . The severe consequences of stasis are emphasized by the fact that the risk of stroke is increased by fivefold for patients with AF compared with unaffected individuals. It is further estimated that 15% of all stroke incidences are attributable to AF, a number that increases significantly with age (461) . In contrast to AF, ventricular fibrillation (VF) is less common but more serious in nature. VF causes an immediate severe reduction in ventricular ejection fraction due to the fast contractions not being coordinated in the different parts of the ventricle. Systemic need for circulation cannot be met, and if continued, VF will result in sudden cardiac death. According to both the spiral wave and leading circle theories for reentry-based arrhythmias, inhibition of K ϩ channels should prolong ERP and exhibit antiarrhythmic effects. This is, however, not necessarily the reality in ventricular arrhythmia, as demonstrated by the SWORD clinical trial (Survival With Oral D-Sotalol) that was preterminated due to increased mortality (440) . The proarrhythmic effect of Dsotalol and other more traditional class III compounds can be explained be several factors. Excessive prolongation of action potentials, especially in situations introducing an extended and slowly decaying phase 3-repolarization, will promote reactivation of voltage-gated Ca 2ϩ channels. This is exactly the basis for EADs that can trigger an arrhythmic event such as the polymorphic ventricular tachycardia, also described as torsades de pointes (TdP), which can eventually degenerate into VF (377) . An additional mechanistic problem from using class III compounds for the treatment of VF is the reverse usedependency associated with many of these drugs (108). Reverse use-dependency describes the phenomenon that the efficacy of the drugs in prolonging the action potentials is poor in tachycardia and good in bradycardia, where there is no need for the drug to function and where the risk of EAD-based triggering of arrhythmias is maximal. It should be mentioned that whereas a delayed repolarization can be antiarrhythmic, a slowed depolarizing phase (triangulation) is proarrhythmic, and a common problem with K ϩ channel blocking compounds is that they induce both effects (185) . The multichannel blocker amiodarone is a fairly safe compound that prolongs the QT interval (indicating prolonged ventricular action potentials), does not induce triangulation, demonstrates no reverse use-dependency, and has very diminutive probability for inducing TdP (209) .
In addition to the increased risk of inducing EADs by inappropriate inhibition of repolarization K ϩ channels leading to triangulation, the large muscle mass in ventricles, compared with atria, further adds to the increased propensity for pro-arrhythmic effects of K ϩ channel inhibition. Electrical heterogeneities among cardiac cells can exist along several axes including the transmural, left-right, and apicobasal axes (50). As described earlier, such electrical heterogeneities can constitute a substrate for arrhythmias as prominent as those obtained by anatomical remodeling or infarcts. This type of heterogeneity can also arise from acute myocardial ischemia and chronic myocardial infarction (25, 87, 447) . In the literature, transmural voltage gradients in particular have received continued interest. In different species including humans, it has been suggested that the ventricular wall is sufficient in thickness to encompass three different areas of cells named endocardial, mid-myocardial, and epicardial areas (56, 293, 427) . Particularly the mid-myocardial cells have been speculated as having prolonged action potentials that can cause electrical heterogeneity during repolarization. This heterogeneity is also recognized as action potential dispersion and can be increased under conditions such as ischemia, bradycardia, and drug application (241, 427) .
To recapitulate, the research in new pharmacological treatments of ventricular tachycardia and VF has been rather unsuccessful, although it has led to a much better understanding of how to avoid pro-arrhythmic effects of new drugs. The current first-line treatment for ventricular arrhythmia is therefore often devices and classical anti-arrhythmic drugs as adjuncts (83, 84) . A detailed description of new attempts is given in the section on pharmacological tools.
D. Remodeling
One of the consequences of sustained fibrillation or congestive heart failure is that these conditions predispose to further fibrillation by inducing changes in the physiological CARDIAC POTASSIUM CHANNELS AND ARRHYTHMIA and anatomical properties of the cardiac tissue. It should be accentuated that fibrillatory events per se can change the overall distribution and function of ion channels in a quantitative and qualitative fashion without evident structural changes. This process is known as electrical remodeling. Hence, we will subsequently give an account of essential changes in ion channel function and distribution as a consequence of remodeling.
Changes in electrophysiological parameters are due to redistribution and up-or downregulation of various ion channels. The exact outcome of remodeling depends on the underlying disease and differs according to whether it is introduced by atrial tachypacing or by congestive heart failure (300). Remodeling can also differ between atria and ventricles, even when originating from the same condition. The following section is therefore divided into separate paragraphs covering atrial and ventricular remodeling, respectively.
Atrial remodeling
AF is a condition that tends to develop or progress over time. A consequence of especially sustained AF is remodeling of the atria. The changes encompass both structural and electrical alternations. Structural remodeling primarily involves atrial dilatation, hypertrophy, and increased amount and changed distribution of fibrotic tissue not able to conduct electrical signals (60, 61, 71) . Electrical remodeling is the consequence of an overall qualitative and quantitative change in ion channel distribution. The combined effects of structural and electrical remodeling result in AF being a self-perpetuating disease if left untreated. The reason for this is that remodeling increases the propensity for triggering events that can initiate future incidences of AF. This will happen in combination with the tissue becoming more vulnerable to electrical disturbances and the development of larger areas of nonconducting tissue that can serve as a substrate for reentry-based AF. Consequently, patients with episodes of paroxysmal AF can progress into persistent and permanent AF, a phenomenon that has been characterized as "AF begets AF" (7, 105, 303, 456) . In addition to being a direct outcome of tachypacing and AF, remodeling of atria can also arise as a secondary effect from cardiac diseases that are not directly related to arrhythmia. These could be congestive heart failure and acute myocardial infarction (300). The following description of remodeling focuses on effects on ion channels as a direct consequence of AF. A brief overview of the effects of remodeling is given in At first sight remodeling might be perceived as a condition resulting in nothing but an unfavorable outcome. Despite the damaging long-term consequences, however, there are acute beneficial effects associated with remodeling. In AF tissue, atrial contraction is significantly increased due to the high frequent initiation of action potentials and corresponding influx of Ca 2ϩ . A very consistent observation in different species challenged with AF or tachypacing is a reduction in voltage-gated L-type Ca 2ϩ channels, while Ttype channels seem to be unaffected (485) . Ca 2ϩ overload is potentially lethal, and the downregulation of L-type channels can be seen as a logical response serving to reduce Ca 2ϩ influx to the myocytes (48, 49, 77, 462, 472) . The acute benefits of decreasing Ca 2ϩ overload via a reduction in L-type Ca 2ϩ channels is, however, jeopardized in the longer perspective. Reduced Ca 2ϩ current will decrease the action potential duration by reducing the plateau phase, meaning a shorter and also more triangulated action potential. This will in theory be proarrhythmic, since ERP is reduced and the risk for EAD-based triggering events is increased. When it comes to an increased propensity for atrial EADs, the situation is not quite as simple. Although triangulation enlarges the vulnerable window for reactivation of L-type Ca 2ϩ channels and thereby EADs, the concomitant reduction in channel number will counteract this tendency. Predicting whether the outcome is an increased or decreased risk for EAD-initiated arrhythmia can be difficult, but EADrelated AF is well-described (58, 378) .
Upregulation of K
ϩ channels is also a prominent contributor to the action potential shortening associated with tachypacing and AF. Several studies showed increased mRNA and protein levels for K ir 2.1 channels that are the main component of I K1 (132, 172, 331, 492) . In contrast, I K1 is downregulated or unchanged when remodeling is based on myocardial infarction or congestive heart failure (240, 345) . This notion emphasizes the complexity of changes and the importance of the condition that provokes the remodeling. It seems justifiable to hypothesize that there may be different types of AF based on the biological mechanism causing the disease. The upregulation of I K1 during AF will contribute to a further reduction in action potential duration and ERP, which is proarrhythmic. Furthermore, it has been demonstrated that increased I K1 can increase the curvature of spiral waves and thereby stabilize rotors and reentry arrhythmias (74, 373).
Also K ir 3.1/3.4 responsible for I KACh is affected by remodeling. The constitutive component of this channel is normally tiny, and a significant I KACh normally requires an increased parasympathetic or vagal tone. Vagal activation is proarrhythmic as the I KACh activation leads to a shortening of ERP and stabilization of rotors (81, 220, 480) . A reduction of I KACh has been reported in conjunction with AF, but it has also been suggested that the constitute component of I KACh is increased as a consequence of AF remodeling leaving a sustained vagally independent current activity that would be proarrhythmic (104, 438).
Remodeling of K V 1.5 channels and thereby I Kur in the context of AF is more equivocal. There have been reports of both a reduction in current density and of no changes (49, 52, 439, 462) . It is a paradox that although only modest or SCHMITT, GRUNNET, AND OLESEN no changes in I Kur have been observed in association with AF, the contribution from this current to repolarization appears very different in AF patients compared with control individuals in sinus rhythm. I Kur inhibition in AF patients prolongs action potential duration, while a reduction in action potential duration is observed in sinus rhythm, probably reflecting a changed relative significance of I Kur due to up-and downregulation of other channels (78, 90, 359) . This truly demonstrates the complexity of remodeling and the importance of considering the entire composition of ion channels when trying to predict the impact of remodeling of a single type of current. In the context of lone AF, it should also be mentioned that some reports have associated lossof-function mutations in KCNA5 encoding K V 1.5 and thereby I Kur to increased risk for AF (322, 476) , and recently KCNA5 gain-of-function mutations (79) have been reported in a number of lone AF patients.
Very recently, Ling and co-workers (70) reported that atrial miRNA-499, which is significantly upregulated in AF, leads to K Ca 2.3 downregulation by binding of miR-499 to the 3'-UTR of KCNN3, and hence is possibly involved in electrical remodeling in AF. can affect action potential duration both directly and indirectly. As expected from a reduction in repolarizing capacity, action potential duration is increased when I to is downregulated. This has been demonstrated in in silico studies and in studies employing cardiac atrial myocytes from rabbit and human (275, 463) . The indirect mechanism relies on the fast activation that can oppose depolarizing inward Na ϩ currents. In a situation of reduced I to , the balance between depolarizing and repolarizing currents can change, thereby resulting in increased action potential amplitude (299) . Na v 1.5 channels may also be influenced by remodeling, but few and conflicting results are reported. Reductions have been demonstrated in tachypaced dogs, and a significant 16% decrease in peak I Na density has also been seen in atrial right appendage cardiomyocytes isolated from AF patients compared with controls (135, 401) . However, other studies on atrial tissue from human AF patients did not observe changes in I Na (49, 132).
Remodeling of the gap junction proteins connexins 40 and 43 is reported in conjunction with tachypacing and AF. There are some discrepancies in the reports concerning the overall expression level of connexins, with data indicating either reduced, enhanced, or unchanged connexin levels (300) . From the perspective of affecting AF, the subcellular distribution of connexins might be of more importance than the total expression level, since this could affect conduction velocity to a larger degree. One of the reported effects of AF-induced remodeling is translocation of connexins from intercalated disks to lateral membranes (224, 351) . Such subcellular distributional changes will augment the heterogeneity of impulse propagation and thereby probably increase the propensity for AF.
Finally, some consequences of remodeling that are not directly related to ion channels deserve to be briefly mentioned. Conditions such as acute ischemia, atrial dilation, and inflammation are likely to contribute to an increased substrate that will prone the maintenance of AF (299) . Atrial dilation, especially in the left atria, causes tissue enlargements. As a result, more reentry circuits can be encompassed, which is proarrhythmic per se (190) . This condition is observed after tachypacing as well as in heart failure (390) . Another important contributor to increased substrates is generation of fibrotic tissue, which is normally encountered in heart failure and is associated with the development of AF (239, 391).
Ventricular remodeling
A prerequisite for understanding the significance of changes in ion channel activity is to view them in the broader context of native cells, intact muscles, and intact organs. This is exemplified when analyzing ventricular remodeling as a consequence of congestive heart failure. The condition is characterized by severe cardiac impairment and the inability to meet the requirements for proper circulation (300). Heart failure significantly increases the risk of ventricular arrhythmias (218) . Approximately half of the death incidents in heart failure patients are related to ventricular arrhythmias, and on top of this atrial arrhythmias are a common companion to heart failure (112). Whereas the hallmark of AF was shortened and triangulated atrial action potentials, the characteristic feature of ventricular remodeling in heart failure is a prolonged ventricular action potential. In the early phase, this will help to partly compensate for reduced ventricular function by improving the contraction strength (370) . The prolongation is primarily due to changes in voltage-gated Ca 2ϩ channels and K ϩ channels. Overall, the conductance through voltage-gated Ca 2ϩ channels is increased. The number of channels is actually reduced, but this is more than compensated for by an increased open probability (73) . It should also be mentioned that changes in Ca 2ϩ handling proteins other than ion channels occur in heart failure. Expression of the Na ϩ /Ca 2ϩ exchanger NXC is enhanced by heart failure, while the expression and function of the Ca 2ϩ -ATPase SERCA2a located in sarcoplasmic reticulum is downregulated (374, 383, 399) . Finally, there is an increased Ca 2ϩ leak from the sarcoplasmic reticulum to the cytosol due to hyperphosphorylation of Ca 2ϩ -release channels or RyRs (388, 479) .
For K ϩ channels, the most consistent change is a reduction in the phase 1 repolarizing I to (300) . The change is due to reduction in the principal ␣-subunit K V 4.3, while the expression of the associated ␤-subunit KChIP2 is unaltered (4, 368, 399, 501) . Another denominator of heart failure remodeling seems to be a reduction in the phase 3 repolarizing I K1 encoded by K ir 2.1, although findings are not as consistent as observed for I to (300, 369, 399, 423) . Of the two remaining phase 3 repolarization currents, there may be a reduction in I Ks , whereas I Kr is reported to be unaffected (300, 399) .
Remodeling of heart failure ventricles causes a few additional changes: reduction in peak I Na but increase in persistent I Na,late , decreased connexin 43 expression, and decreased pacemaking I f current (3, 375, 428, 430, 431, 500) . The ventricular reduction of HCN2 and HCN4 subunits conducting I f is another example of opposite consequences of remodeling in atria and ventricles, since these subunits are upregulated in failing atria (500).
The increased strength of contraction in early remodeling comes at a price of increased risk of arrhythmias for several reasons. The downregulation of the repolarizing reserve K ϩ currents will postpone the phase 3 repolarization phase and increase the vulnerable window for reactivation of voltagegated Ca 2ϩ channels. Together with the increased open probability of these Ca 2ϩ channels, the overall consequence SCHMITT, GRUNNET, AND OLESEN is a marked increase risk for EADs that can trigger arrhythmic events (193, 242, 314) . As I Kr is the main repolarizing current not downregulated in heart failure myocardium, there is an excessive risk of action potential prolongation, triangulation, and arrhythmia when exposing patients to drugs that inhibit this channel. I Kr inhibition is an unintended property of many drugs used in the clinic, and extra care should be taken with such compounds in the event of heart failure (424) . From the perspective of prolonged ventricular action potentials and increased risk of EADs, heart failure can be viewed as a kind of acquired LQTS (76) .
The reduction of I K1 has also been associated with proarrhythmia due to increased risk of DADs due to the important function of I K1 in setting the resting membrane potential in the diastole. Under normal conditions, the high open probability of I K1 at resting membrane potential results in a correspondingly low membrane resistance. The low resistance will decrease the amplitude of abnormal depolarizations such as DADs. In contrast, when I K1 is reduced, the diastolic membrane resistance is increased, and a DAD will result in larger current amplitude with higher chance of reaching the threshold for evoking a premature action potential (350) . These physiological mechanisms emphasize the somewhat ignored fact that a high diastolic K ϩ conductance can be a very important antiarrhythmic parameter, both to decrease the likelihood for DADs to elicit inappropriate action potentials, as well as to set the stage for the next systole by affecting the release from inactivation of Na ϩ channels. The antiarrhythmic effect of some of the recent activators of K V 11.1 channels and thereby I Kr might be explained by increased diastolic K ϩ conductance (169 -171). Importantly, this could also be a parameter that discriminates application of K V 11.1 activators from short QT mutations such as K V 11.1-N588K (154).
Furthermore, the remodeling of Ca 2ϩ handling proteins other than ion channels contributes to the proarrhythmic effects. The combination of increased Ca 2ϩ leak from sarcoplasmic reticulum (SR), reduced SR uptake due to decrease SERCA2a function, and increased Na ϩ /Ca 2ϩ exchanger (NCX) function is problematic for two reasons. First, the general reduction in SR Ca 2ϩ content will decrease contractile function. Second, the increased cytosolic Ca 2ϩ concentration in combination with increased amount of NCX will increase cellular Ca 2ϩ efflux at the expense of increased Na ϩ uptake. This electrogenic transport can provoke DADs and trigger arrhythmias (300).
Finally, the increase in the persistent Na ϩ current I Na,late will participate in the prolongation of ventricular action potentials and increase the risk for EADs (428, 430) . The downregulation of HCN subunits and thereby I f can cause bradycardia and contribute to cardiac decompensation (6).
IV. PHARMACOLOGICAL TOOLS FOR ADDRESSING CARDIAC K ؉ CHANNEL FUNCTION
The use of pharmacological tool compounds has been of immense value for understanding the physiology of cardiac electrical activity and pathophysiology of cardiac arrhythmias. The following section focuses on initiatives targeting K ϩ channels and introduces the ideas behind some of the novel approaches for developing antiarrhythmic drugs and the experiences with them. The main body will be on strategies for targeting AF, but an outline on new pharmacological treatment of VF by K ϩ channel modulation is also included.
A. Strategies for Treatment of AF
The two principal strategies for treating AF are rhythm and rate control, respectively. The aim of rhythm control is to restore and maintain normal sinus rhythm. In contrast, rate control aims to reduce the ventricular impact of AF by protecting the ventricles from the fast atrial electrical activity. In other words, rate control will leave the atria fibrillating and prevent excessive conduction from atria to ventricles. This is accomplished by the application of beta blockers, calcium channel blockers, digoxin, or amiodarone that prolongs refractoriness in the AV node and slows conduction through the AV node.
Considering these aims, it would be expected that rhythm control, which targets AF rather than its downstream consequences, would be preferential to rate control. This has, however, not been justified by trials such as AFFIRM, RACE, PIAF, STAF, and HOT CAFÉ that compared the ability of rhythm versus rate control to reduce hard end points such as stroke and death (68, 137, 181, 324, 466) . The nonsuperiority of rhythm control in these trials is surprising, since it could be expected that reversion of AF to normal sinus rhythm would decrease blood stasis, reduce the risk of stroke, and concomitantly improve hemodynamic parameters. An explanation for the nonsuperiority of rhythm versus rate control might be that the RACE and AFFIRM trials did not include younger symptomatic AF patients without underlying heart diseases. Another reason might be the applied strategy for analyzing the data. Based on the AFFIRM information, it was demonstrated for example that sinus rhythm was an independent predictor of reducing the risk of death, but simultaneously increased overall mortality (hazard ratio ϭ 1.49) (86, 337) . The explanation for this overall increase in mortality is likely due to the ventricular proarrhythmic effects associated with some of the drugs developed for rhythm control, as demonstrated by the CAST and SWORD study (110, 119, 440) . In a recent study on 26,130 Canadian AF patients with a longer follow-up, the relative advantages of the two treatment paradigms were time dependent. The rhythm control group showed a slight increase in mortality during the first 6 months, equal mortality until year 4, and a lower mortality than the rate control group after 5 years, indicating a long-term superiority of rhythm control (189) . For these reasons, the search for atrial-selective drugs without extracardiac toxicity and ventricular proarrhythmic effects is the favorable approach when designing new antiarrhythmic drugs. The current guidelines also still support restoration of sinus rhythm in younger AF patients as first-line treatment (128, 129) .
Triggers and reentry propagation of electrical signals in a changed substrate are the key mechanisms of AF as mentioned above. Inhibition of K ϩ channels has proven effective in prolongation of the effective refractory periods and interruption of reentry-based arrhythmias. Such compounds constitute the class III antiarrhythmics according to the Vaughan-Williams classification. The typical class III drugs are dofetilide and ibutilide, but sotalol and multichannel inhibitors such as amiodarone and dronedarone also exhibit class III properties (69, 235, 344) . All these drugs inherently influence both atrial and ventricular signaling, and it is evident that many of their adverse effects would be reduced if they solely targeted atrial ion channels.
Substantial preclinical and clinical information has been gathered for dronedarone, one of the anti-arrhythmic drug newcomers. While this drug was developed to preserve the efficacy of amiodarone and reduce adverse effects by deleting iodine in the molecule, the outcome remained equivocal. Compared with amiodarone, dronedarone seems less efficacious in a clinical setting. The clinical study ATHENA comprised patients with paroxysmal or persistent AF (179) . Compared with the placebo group, dronedarone resulted in significant reduction in cardiovascular admissions and mortality (180) . The DIONYSOS study included an end point of direct comparison of amiodarone and dronedarone. Dronedarone turned out to be less efficacious in patients with persistent AF, but amiodarone had the advantage of better tolerance (177) . Noteworthy, the United States Food and Drug Administration (FDA) recently issued a safety announcement stating that the use of dronedarone can be associated with hepatic failure. Furthermore, dronedarone is counter-indicated for heart failure patients due to increased premature death in this patient population, as demonstrated in the preterminated ANDROMEDA study (222) . The diverse experiences with the development of dronedarone emphasize the need for careful selection of new antiarrhythmic drugs and thorough preclinical understanding of mode of action. Better patient stratification might also help new antiarrhythmic drugs to succeed in passing clinical development.
Current drug discovery and development activities for the treatment of AF target atrial-specific K ϩ channels or aim at selective inhibition of atrial Na ϩ channels. This latter approach takes advantage of the fact that resting membrane potential is more positive in atria compared with ventricles. Consequently, Na ϩ channels are more inactivated in atria, which can be exploited to generate state-dependent and thereby selective inhibitors of atrial Na ϩ channels. Since this review focuses on K ϩ channels, no further introduction to state-dependent Na ϩ channel inhibition will be included. More comprehensive overviews can be found in References 16 and 153.
I Kur blockers
Functional I Kur is generally believed to be absent from ventricles (13) . Thus blocking I Kur has been perceived as an attractive strategy for developing a new drug against AF (125) . However, inhibiting I Kur by low concentrations of 4-aminopyrimidine or AVE0118 in atrial trabeculae from individuals in sinus rhythm led to shortened action potentials. This counterintuitive finding is explained by an elevated plateau potential that allows for more prominent I Kr and I Ks activation and thereby accelerated repolarization (454) . The results emphasize the importance of addressing modulations of ion channels in the perspective of the orchestrated function of all other ion channels in play. This is further underscored by the fact that inhibition of I Kur causes different effects in remodeled tissue from AF patients. Here the triangulated action potential gives room for less elevated plateau potentials, and consequently I Kur inhibition increases action potential duration (454) . It is still an open question whether a pure I Kur blocker will be sufficient for AF suppression. It is worth keeping in mind that chronic AF in humans might reduce K V 1.5 expression and thereby I Kur density (78, 439) . Also it should be mentioned that the importance of I Kur in humans seems to be less pronounced than suggested from preclinical animal models (336) . In addition, I Kur density is diminished at high atrial heart rates as seen in AF (122) . Furthermore, a safety concern is evident since it has been demonstrated that loss-of-function mutation in KCNA5 giving rise to reduced I Kur is associated with familial AF (322, 476) . A number of K V 1.5 channel inhibitors have been or are in development for treating AF, and the applicability of I Kur inhibition as a valid approach for treating AF is likely to be clarified in the future. Some of these compounds are AVE0118 (IC 50 1.1 M), which also has affinity for I to and I KAch (142); DPO-1 as a use-dependent open I Kur channel blocker with some affinity for I K1 and I Ks (230, 361) ; and more selective compounds such as XEN-D0101 and XEN-D0103 with human atrial I Kur IC 50 values of 241 and 154 nM, respectively (125) . It has generally proven difficult to obtain good selectivity among K v channel subtypes, as many drugs interact with highly conserved residues in the central cavity. Using alanine-scanning on K V 1.x channels, new drug binding sites have been identified on pockets formed by the backsides of several transmembrane segments, indicating a possible avenue for overcoming this problem (277) .
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I KAch blockers
The K ϩ current I KAch composed of K ir 3.1/K ir 3.4 subunits is another atrial-selective target that has not been as extensively investigated as K V 1.5 channels, but evidence has been accumulating, particularly in recent years, for this to be an interesting target (358) . As for K V 1.5, the rationale for inhibiting this channel is to obtain selective prolongation of the atrial effective refractory periods. Interesting I KAch inhibitors are NTC-801 with an IC 50 of 0.7 nM as well as NIP-151 and NIP-142 with IC 50 values of 1.6 and 640 nM, respectively (269, 297, 416, 418) . Noteworthy, many multichannel inhibitors developed for treatment of AF display affinity for I KAch . These include amiodarone, dronedarone, AVE0118, E-4031, vernakalant, sotalol, and flecainide (121, 142, 163, 288, 448) .
Other concepts
Preclinical evidence points to Ca 2ϩ -activated K Ca 2.x channels as a target that possesses functional atrial selectivity, and K Ca 2.x channel inhibition has demonstrated to be efficient in terminating acutely induced AF in various animal models (101, 102, 396). These studies have recently been extended in dogs with atrial fibrillation induced by atrial tachypacing. Atrial tachypacing increased whole cell and single channel K Ca 2.x current. Pharmacological inhibition of K Ca 2.x increased action potential duration in an atrialselective manner and demonstrated antiarrhythmic properties in dogs (357) . For a comprehensive overview or recent development of drugs targeting AF, see also Reference 153.
Some attempts have also been made to investigate the antiarrhythmic potential of modulating the I K1 current. However, since I K1 is by no means an atrial-selective target, it is debated whether increased or decreased activity will be beneficial. Various studies demonstrated that increasing I K1 is proarrhythmic due to stabilizing rotors (252, 446) . However, antiarrhythmic effects have also been observed after I K1 activation (252).
B. Strategies for Treatment of VF
In recent years, new developments of K ϩ channel modulators have been sparse as a consequence of the proarrhythmia associated with traditional class III antiarrhythmics and the current first-line treatment with implantable electronic devices (84, 86, 110, 119) . However, there have been some preclinical approaches investigating the idea of an increased repolarization reserve as a new principle for treating ventricular arrhythmias. Test molecules have been developed activating all phase 3 repolarizing K ϩ currents I Kr , I Ks , and I K1 carried by K V 11.1, K V 7.1, and K ir 2.1, respectively, but it is primarily activators of K V 11.1 that have been thoroughly investigated.
The idea about an increased repolarization reserve as an antiarrhythmic strategy appeared as a logical extension of the proarrhythmic effects observed by prolonging the ventricular action potential with class III drugs. It was demonstrated that proarrhythmia is primarily due to the inhibition of K V 11.1 channels, and it became a prerequisite in drug development to screen potential drug candidates for their ability to inhibit this channel. A number of high-throughput assays were developed for the purpose, and as a result of screening hundreds of thousands of compounds for K V 11.1 inhibition, a number of activators of this channel also appeared. Several companies pursued the idea that the conditions or diseases associated with prolonged QT intervals and underlying ventricular action potential prolongations could be normalized by the application of K V 11.1 channel activators. From a theoretical perspective, the primary antiarrhythmic effects of such compounds would be shortening of the action potential duration and reduced triangulation leading to narrowing of the vulnerable window leaving less room for EADs that can trigger an arrhythmia. Since K V 11.1 channels deactivate slowly during the early phase 4, an increased current will further help antagonize DADs here. Decrease in electronic heterogeneity could be another beneficial parameter. Relevant indications could be congenital and acquired long QT syndromes, heart failure, and prolonged QT in association with AF, ischemia, diabetes, etc. K V 11.1 channels show very characteristic inactivation properties with fast inactivation upon depolarization and fast recovery from inactivation upon repolarization (FIGURE 11A). Many K V 11.1 channel activators affect these properties by reducing inactivation or promoting recovery from inactivation. A reduction in relative inactivation, being equal to a rightward shifted inactivation curve, will increase the overall K V 11.1 current. Compounds with such properties include NS1643 and NS3623 (both NeuroSearch), PD-307243 (Pfizer), and A-935142 (Abbott) (151, 168, 169, 411, 498) . RPR260243 (Sanofi-Aventis) utilizes a different mechanism of action, as it slows K V 11.1 channel closure (deactivation) corresponding to an increase in macroscopic I Kr (203) . Importantly, the pharmacological effect of these compounds is different from the biophysical properties revealed for a K V 11.1 channel mutation that has been associated with the SQTS (154).
The antiarrhythmic properties of this new compound class were demonstrated experimentally ex vivo and in vivo. In patch-clamp studies, NS1643 and NS3623 shorten ventricular action potentials when recorded from acutely isolated single cells (FIGURE 11B) , and the same notion holds true in isolated papillary muscle. Importantly, an increased ability to withstand triggering activity in the form of mimicked EADs was also demonstrated (100, 168, 169) . Similar results have been obtained with A-935142 in guinea pigs and dogs (411) . PD-118057 has also been tested ex vivo in iso- A: K V 11.1 gating kinetics. B: activation of K V 11.1 with the tool compound NS1643 in acutely isolated cardiomyocytes from guinea pig. The response of cardiomyocytes to simulated EADs was assessed after an elicited action potential; a train of 10 -20 50% subthreshold stimuli was applied either at control situations after full repolarization (a and c) or to induce EADs at APD90 (b and d). In the absence of NS1643, subthreshold stimuli applied at APD90 were able to induce EAD events every time the protocol was applied, and prolongation of the action potential was continued even after cessation of current injection (b). Upon application of 10 M NS1643, the premature train of stimuli was not able to trigger any abnormal activity, and application of the drug thus led to a stable action potential (d). Superimposed traces for subthreshold stimuli applied at APD90 in the absence or presence of NS1643 are shown in e, left. Current injection protocol is shown in e, right. [B from Hansen et al. (168) .] lated rabbit and canine wedge preparations with somewhat opposing results. A clear antiarrhythmic effect was observed in the rabbit wedge and included the expected action potential shortening, but also reduced dispersion. In contrast, canine wedge studies resulted in increased dispersion and pacing-induced polymorphic ventricular tachycardia (334, 498) . In intact isolated hearts, NS3623 has demonstrated antiarrhythmic properties such as a decrease in QT variability, and a tendency towards reduced global dispersion when addressed as a reduction in T peak -T end intervals, as well as a marked reduction in number of extrasystoli (170) .
In vivo NS3623 has been tested in anesthetized and conscious guinea pigs. In line with theoretical considerations, the measured and corrected QT interval was reduced in both conditions. Furthermore, NS3623 reverses drug-induced QT prolongation (171) . In rabbits, NS1643 has demonstrated antiarrhythmic properties in a pharmacological and nonpharmacological model for ventricular fibrillation. In the pharmacological model, the combined proarrhythmic effect of the class III drug dofetilide together with the ␣1-adrenergic receptor agonist methoxamine could be prevented by NS1643. In a more physiological model, atrioventricular block and subsequent 3-wk bradypacing resulted in ventricular extrasystoli and short runs of TdP like arrhythmias. Both conditions could be prevented by NS1643 (103). Although the models are promising, it should also be mentioned that proarrhythmic effects have been associated with K V 11.1 channel activators, although some of these might be unspecific effects (162, 259). In terms of therapeutic application, K V 11.1 channel activators probably have the highest chance of success in conditions with extensive action prolongation that can subsequently be normalized by this new compound class.
For K V 7.1 channels and I Ks , only limited experience is available on pro-or antiarrhythmic effects of increasing this current, with the benzodiazepine R-L3 being the central compound. R-L3 reverses pharmacologically induced type 2 LQTS (induced by I Kr inhibition), shortens action potential duration, and decreases triangulation. The compound activates heterologously expressed K V 7.1 channels, but has no effect on the K V 7.1/KCNE1 complex that mimics native I Ks (371, 384) . R-L3 also reduces the effective refractory period, which might indicate proarrhythmic activity by increasing the risk for atrial fibrillation (310) . More comprehensive overviews of exact mode of actions and anti-and proarrhythmic properties of K V 11.1 and K V 7.1 activators are given in References 155 and 162.
Another innovative approach to address cardiac ion channels has been the development of activators of I to . Applying the tool compound NS5806 (NeuroSearch) in isolated canine ventricular myocytes increased peak currents significantly and slowed inactivation kinetics. Furthermore, in coronary-perfused wedge preparations, NS5806 recapitulated the features of Brugada Syndrome phenotype visible as increase in phase 1 and notch amplitudes (62) . The effect was later shown to be dependent on the presence of the I to subunit K channel interacting protein (KChIP) 2 (65, 263) . Accordingly, the transmural KChIP2 gradient across the ventricular wall led to differential effects of NS5806 in epi-, mid-, and endocardial cells (65) . A study comparing NS5806 in canine atrial and ventricular myocytes showed a different response in the atria, where the addition of drug had only mild effects on phase 1. Instead, the upstroke velocity was significantly decreased, which could be ascribed to a strong inhibition of I Na in the atria (63) . Although NS5806 in addition to Na V 1.5 does affect other potassium channels such as K V 1.4 and K V 1.5, it represents an interesting tool compound in the context of heart failure (HF). HF, amongst others, is characterized by an action potential prolongation due to remodeling the repolarizing currents I to and I Ks (reviewed in Ref. 88 ). The reduction in I to is due to the reduction of K V 4.3 channels (202) . NS5806 was used in a tachypaced-induced canine model of heart failure and was able to restore phase 1 action potential morphology in wedge preparations from HF dogs (85) . Despite the risk of being proarrhythmic, this tool compound provided a proof-of-concept that I to activators might be useful for treatment of HF.
V. CONCLUSIONS AND PERSPECTIVES
The molecular studies of the diverse cardiac potassium channel subtypes have allowed a detailed picture of their individual structures and regulatory mechanisms to emerge. By addressing the significance of accessory subunits and influence of posttranslational modifications, it has also been widely possible to translate these molecular correlates into the endogenous cardiac K ϩ currents. Yet most of the stateof-the-art techniques employ heterologously expressed channels or depict snap shots of cardiac tissue, and hence only partially reflect processes in vivo. Accordingly, a larger challenge that still remains is to understand how these "actors in the still picture" behave in dynamic play and change their function relative to each other both in the short term (changes in heart rate, sympathetic tone, Ca 2ϩ level, posttranslational modifications) and long term (epigenetic changes, remodeling). These changes of the basic biological conditions of the tissue determine whether the stable heart rhythm is maintained or an arrhythmia is triggered.
We have in this review addressed the concerted action of the repolarizing cardiac K ϩ currents, while also seeing them as individual currents. The use of selective pharmacological tools, both channel-subtype-specific toxins and organic molecules, has proven valuable to dissect the role of the individual channels in intact organisms. One result of these pharmacological studies combined with expression analysis and other functional investigations is the identification and CARDIAC POTASSIUM CHANNELS AND ARRHYTHMIA verification of the fairly atrial-specific repolarizing currents I Kur , I KAch , I KCa , and I K2P . The role of the first two channels in the atria has been known for a number of years, whereas the significance of the latter two is new and may pave the way for new treatment paradigms for AF.
Over the past 20 years, the mutations in single cardiac ion channels have been a rich source of information about the role of each channel subtype in arrhythmogenesis and have fostered the concept of monogenetic arrhythmic diseases. The significance of these variants is currently being rewritten on the background of the exome data becoming available from large cohorts showing their presence in the general population and calling for a stricter interpretation.
The limited penetrance of some of the disease-causing mutations and the fact that both gain-of-function and loss-offunction mutations in the same channel can cause a similar disease indicate that there are conditions of the cardiac tissue we probably need to take into consideration for each patient to understand the outcome of a changed K ϩ channel function. Great effort is made to generate various disease models in animals to clarify this issue. Yet, because the distinct and complex electrophysiological properties of cardiomyocytes differ among species, the use of isolated cardiomyocytes from model animals has limitations. Since certain smaller animals are quite dissimilar to humans, especially from a cardiac point of view, extending the conclusions to human arrhythmogenesis is applicable only to a limited degree.
The best translational studies to provide us with an understanding of the specific role of a given K ϩ channel on the background of the patient's own biological background use fresh human cardiac tissue, often removed in open chest operations with extracorporal circulation. To investigate specific genetic variants, the use of induced pluripotent stem cells generated from the patient's skin biopsies or blood has fostered hope for the development of true personalized medicine.
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